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ABSTRACT
Hematopoietic stem cell transplantation (HSCT) is used in treating many diseases, mainly malignant
hematological disorders. It is an intensive treatment often complicated by organ injuries. Non-
transferrin-bound  iron  (NTBI),  as  an  inducer  of  free  oxygen  radicals,  is  a  potential  factor  in  the
pathogenesis of these complications. We studied the appearance and timing of NTBI in transplant
patients and the possibility to prevent the occurrence of NTBI by binding it with apotransferrin
administration.
Ten adult patients with hematological malignancy undergoing allogeneic HSCT with myeloablative
conditioning were enrolled to study the timing of the changes in the serum levels of iron parameters in
the peritransplant period.  None of the patients were NTBI-positive at baseline. The bleomycin-
detectable  iron  (BDI)  -assay  was  used  to  assess  NTBI.   During  the  first  two  days  after  starting  the
conditioning the mean total iron concentration doubled from an initial level to a peak on day -4 before
HSCT (day 0).   The transferrin levels decreased continuously and fully saturated transferrin was
observed by day -4, simultaneously with the occurrence of NTBI.  The mean transferrin saturation
remained above 80% thereafter. NTBI was detectable in the majority of patients until day +11,
remaining present in half of the patients through the study period to day +14. Transferrin saturation
level of 80% was found to be a significant threshold for the appearance of NTBI.
The timing and length of the appearance of NTBI were also studied in 16 patients who underwent
autologous stem cell transplantation.  The transferrin saturation levels were within the normal range at
baseline. After a steep rise within the first days after the initiation of conditioning the maximum
saturation levels were reached approximately on day 4-6 from the start of treatment.  The levels
started to descend one week after the beginning of each regimen. None of the patients were NTBI-
positive  at  baseline.  In  all  but  three  of  the  patients  NTBI  was  detected  variably  during  the
transplantation process. The mean time from the first to the last NTBI-positive sample was 6.1 days.
The disappearance or marked reduction of the NTBI-positive samples coincided with the recovery of
the bone marrow function demonstrated by the rise of the leukocyte counts.
Eight patients with acute leukemia treated with conventional chemotherapy were also studied for the
timing of the changes in iron parameters during the peritreatment period. The mean transferrin and
transferrin saturation levels were below the reference range at the baseline, and the transferrin level
remained subnormal thereafter. The transferrin saturation showed a steep rise above 90% by day 3
from the start of chemotherapy, and remained above 80% through the study period. NTBI was
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detected already at baseline in nearly 40% of the samples. NTBI could be demonstrated in all patients
during the study period of 20 days. The mean duration of NTBI-positivity was 15.6 days.
Six consecutive adult patients with acute leukemia, treated with myeloablative conditioning for
allogeneic HSCT received a single dose of apotransferrin on day +3 after the transplantation. After the
apotransferrin injection NTBI disappeared from the sera of all patients. NTBI reappeared 12-24 hours
after the apotransferrin injection in 4 patients and after 6 days in one, one patient remained NTBI
negative through the 12-day follow-up period.
Twenty allogeneic transplant patients were enrolled to receive repeated doses of apotransferrin.  The
ten patients in our first study who underwent HSCT but were not given apotransferrin were used as
controls. Twelve patients were randomized to receive the study drug at two dose levels. A low-dose
(340 mg/kg) group (n= 6) received a single loading dose (100 mg/kg) at the start of conditioning
therapy  on day -6 before HSCT,  followed by nine maintenance doses (26 mg/kg) every other day.
The medium-dose (610 mg/kg) group (n= 6) received four loading doses (100 mg/kg) on four
consecutive days, starting on day -6, followed by eight maintenance doses (26 mg/kg) every other
day.  In the second part, the high-dose (1040 mg/kg) study, eight patients received a higher dose (115
mg/kg) given as four daily doses, from day -6 onwards, continuing every second day until day +7
after HSCT.  In this group five of the eight patients had transferrin saturation ? 80% and were NTBI
negative through the study period.  With lower doses there was a nonsignificant trend towards fewer
days with demonstrable NTBI compared to the controls.  Repeated doses of apotransferrin were
followed by a steep rise in serum iron in a dose-dependent way.
In an in vitro-study we investigated the effect of NTBI on erythroid (BFU-E) and granulocyte-
macrophage (CFU-GM) colony formation and the effect of binding NTBI with apotransferrin.
Hematopoietic progenitors were cultured with different concentrations of NTBI in the form of ferric
nitrilotriacetic acid (FeNTA). Parallel cultures were performed after the preincubation of FeNTA with
apotransferrin.  NTBI inhibited colony formation and reduced the size of the colonies. Preincubation
of FeNTA with apotransferrin diminished the inhibitory effect of FeNTA and increased both the
number and the size of colonies.
In conclusion, we showed that NTBI appears regularly during the peritransplant period in HSCT.
NTBI has been shown to cause cellular and organ toxicity, and thus it may contribute to the
complications of HSCT. Therefore we assessed the possibility to bind NTBI during the peritransplant
period with apotransferrin administration. The appearance of NTBI could be prevented or reduced by
apotransferrin.  The clinical utility of apotransferrin administration and its effects on transplantation
outcomes remain to be investigated in further studies.
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1. INTRODUCTION
Iron is an essential component of the human body.  It is one of the most efficiently recycled
agents. The largest proportions of iron are found as functional iron in hemoglobin and
myoglobin, and it is also an important component of many enzymes. A substantial amount of
iron is stored as ferritin and hemosiderin. Although essential to nearly all cells, iron can also
be toxic due to its propensity to form oxygen radicals that damage cells.
Quantitative deviations of total body iron lead very often to morbidity. Iron deficiency
anemia is the most common type of anemia. In disorders with ineffective erythropoiesis, e.g.
thalassemias  and  congenital  dyserytropoietic  anemias  (Ganz  and  Nemeth  2012b),  or  after
repeated transfusions, excessive amounts of iron accumulate in the organism and may cause
or contribute to organ damage. Iron uptake is strictly regulated, but there is no mechanism to
actively export iron from the body; usage of iron is almost a closed circuit. Iron is passively
exported out of the body only by shedding of intestinal epithelium or menstrual bleeding.
Hematopoietic stem cell transplantation is an intensive treatment, which may interfere with
iron homeostasis in many ways. The underlying disease to be treated with HSCT can cause
anemia, or sometimes iron overload. Many transplant patients have previously received
substantial numbers of blood transfusions. Intensive cytotoxic treatment, conditioning, before
the transplantation causes cessation of red cell production and reduction in the utilization of
iron. Conditioning can also reduce the production of the main iron-carrying protein,
transferrin, in the liver, and injury of liver cells may cause release of storage iron. Some
patients need blood transfusions for a prolonged period after the transplantation.
The impact of iron overload in stem cell transplantation has been unclear, and there are still
many open questions. Until recent years there were no effective and in practice feasible ways
to treat iron overload if phlebotomy could not be applied because of anemia; this is the case
in many transplant patients. For this reason clinical investigation on the impact of transplant-
associated iron overload has not been very active until in recent years, when the situation has
changed essentially.
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In the 1990s it had become apparent in our own experience and in publications from
elsewhere (Or et  al 1987, Antila et  al 1992, Angelucci et al 1997) that the interpretation of
laboratory tests for iron load, especially when ferritin was used as a surrogate, was often
problematic.  Excessively high ferritin levels were sometimes seen in patients with only a
limited number of red cell transfusions in the history, and the significance of such findings as
an indicator of iron load was uncertain. The question of non-transferrin-bound iron and its
possible role in transplantation complications gained increasing interest. At this time the
Finnish Red Cross Blood Transfusion Service had developed a human apotransferrin
concentrate that could be used clinically. This offered potential means to eliminate or reduce
free iron in the process of stem cell transplantation and thereby diminish the risk of reactive
oxygen radicals causing organ injury. Accordingly, we decided to evaluate the appearance of
free iron in stem cell transplant patients and the possibility to bind it with exogenous
apotransferrin.
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2. REVIEW OF THE LITERATURE
2.1. Hematopoietic stem cell transplantation (HSCT)
HSCT is used to replace blood-forming tissue damaged by a blood disease or intensive
cytotoxic treatment. In transplantations from another person, the effect of the donor´s
immunological cells on the malignant cells, the so called graft vs. leukemia or graft vs.
malignancy effect, is also utilized. The treatment of a malignant blood disorder is the most
common indication for hematopoietic stem cell transplantation, but some non-hematological
malignancies, as well as non-malignant blood diseases and some rare inherited
immunological and metabolic disorders, have also been treated with HSCT.
In allogeneic transplantation the donor is another person, in syngeneic transplantation an
identical twin. In autologous transplantation the graft has been earlier harvested from the
patient him/herself.
2.1.1. Conditioning
Before the transplantation, the patient is given a preparative or conditioning regimen which
consists  of  cytotoxic  drugs  and  often  also  includes  radiotherapy.  The  aim  with  the
conditioning is to destroy the malignant or abnormal cells, and, in allogeneic transplantation,
also to depress the immunological system of the patient to prevent rejection. In conventional
full-intensity, myeloablative, transplantations the conditioning regimen has most commonly
consisted of total body irradiation (TBI) or high-dose busulphan combined with large doses
of cyclophosphamide although there have been many variants. In the recent years, the
application of reduced intensity (RIC) or reduced toxicity conditioning has markedly widened
the  indications  of  allogeneic  stem  cell  transplantation  and  the  number  of  patients  who  can
benefit from this treatment modality (Ljungman et al 2010).   There  is  a  wide  spectrum  of
such regimens in use (Gratwohl and Carreras 2012).
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In autologous transplantations for lymphoma, the conditioning usually consists of high doses
of several cytotoxic drugs, for example carmustine, etoposide, cytarabine, cyclophosphamide
(BEAC). The conditioning in autologous transplantations for myeloma is usually based on
high-dose melphalan.
2.1.2. Donor in allogeneic transplantation
A prerequisite for the prevention of graft rejection is a good match of tissue antigens between
the donor and the patient. A human leukocyte antigen (HLA)-identical sibling is usually an
optimal donor. If such a donor is not available, an unrelated donor identical in HLA-A, -B, -
C, -DRB1 and DQB1 antigens is searched for (Petersdorf et al 2007, Nowak 2008).  Often a
difference between the recipient and the related or unrelated donor in one of the ten antigens
(alleles) of these five antigen pairs can be acceptable. An identity of DPB1 antigen is
desirable. Generally, the better the match, the better the outcome, although this issue has
become increasingly complicated with the development of tissue typing methods and the
understanding of the significance of the findings. Until recent years, a majority of the donors
have been HLA-identical siblings. In Finland a good sibling donor can be found for
approximately 25% of the patients.
A donor can also be searched for in registries of voluntary unrelated donors.  As the number
of possible tissue antigen combinations is huge, the number of donor candidates has to be
very large to permit a significant chance of finding a donor. There are donor registries in
numerous countries, and the total number of donor candidates in these registries is about 25
million (Bone Marrow Donors Worldwide 2015). In international collaboration, a donor
search for a patient can be carried out in most of these registries. As a result, a suitable donor
can at present be found for a large majority of patients.  If there is a choice, a sibling donor is
in most cases still to be preferred, but with the development of tissue typing and increasing
knowledge of the importance of tissue type match, the outcomes of transplantations from
unrelated donors are now essentially similar to those from a sibling donor (Gluckman 2012).
Haploidentical transplantations, usually from a non-HLA-identical family member, are at
present a topic of keen interest and clinical evaluation (Bashey et al 2013, Di Stasi et al 2014,
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Martelli et al 2014). Strategies to minimize the adverse effects of tissue type mismatch in this
kind of transplantations have been developed, and the results look promising. The next few
years will show the role of haploidentical transplantations in the management of patients.
2.1.3. Graft
In earlier years the source of hematopoietic stem cells for transplantation was always bone
marrow, usually harvested in general anesthesia from the iliac crests and sometimes
additionally from the sternum. The total volume harvested for an adult patient is usually in
the order of 700-800 ml, depending on the size of the recipient and the cell count of the graft.
If the ABO blood groups of the donor and the recipient differ leading to an incompatible
blood transfusion, red blood cells and plasma are removed from the graft.
At the present time, a majority of grafts are collected from peripheral blood (Gratwohl et al
2013).  In steady state, there are very few hematopoietic stem cells in the blood and thus
harvesting a sufficient graft is not in practice possible. However, with the administration of a
hematopoietic growth factor, usually granulocyte growth factor G-CSF, enough stem cells
can be mobilized from the marrow to allow a successful stem cell harvest from the blood. A
cell fraction containing the hematopoietic stem cells is collected using a cell separator.
Advantages for the donor with the use of blood stem cell grafts are that no anesthesia is
needed and repeated bone marrow aspirates can be avoided. The recipient´s blood cell counts
recover somewhat faster than after bone marrow transplantation, but the risk of graft-versus-
host disease (GVHD), particularly chronic GVHD is higher when a blood stem cell graft is
used (Apperley and Masszi 2012).
Umbilical cord blood contains large numbers of stem cells, and therefore it can be used as a
stem cell graft  (Gluckman 2012). An advantage of this method is that the criteria for tissue
antigen match are less stringent than with bone marrow or peripheral blood stem cell grafts.
The volume and thereby the number of stem cells in a cord blood graft is relatively small, and
therefore cord blood grafts have been earlier mainly used in pediatric transplantations.
However,  with the use of two cord blood units the stem cell  numbers are usually sufficient
for transplantations in adults, and the numbers of such transplantations have markedly
increased until recent years (Passweg et al 2012, Passweg et al 2015).
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Autologous stem cells are usually collected from peripheral blood of the patients at a suitable
time according to the treatment regimen. Bone marrow harvest may be used if peripheral
collection is not successful or feasible.
2.1.4. Complications of HSCT
HSCT is an intensive treatment, which can lead to many complications. The principal
mechanisms are infections, toxic effects caused by conditioning, and immunology (Figure 1).
In autologous HSCT the complications are mainly based on toxic effects and infections.
acute GVHD
chronic GVHD
Bacteria
Pneumococci
CMV
EBV
Herpes zoster
Aspergillus
Pneumocystis jiroveci
VOD
TAM
Obstructive bronchiolitis
Complications after allogeneic HSCT, typical timing. CMV= cytomegalovirus, EBV= Epstein-Barr virus,
VOD = veno-occlusive disease, TAM= transplantation-associated microangiopathy.
60 12 2418
Time in months
Figure 1.  C mplications after allogeneic HSCT, typical timing.
CMV= cytomegalovirus, EBV= Epstein-Barr virus, VOD = veno-occlusive disease, TAM=
transplantation-associated microangiopathy.
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Rejection of the graft is uncommon when malignant blood diseases are treated using
conventional fully myeloablative conditioning. If the donor is an HLA-matched sibling, the
risk of rejection is in the order of two per cent (Anasetti et al 1989).  If the donor is a non-
HLA matched relative or unrelated, the risk is greater. If conditioning with strongly reduced
intensity is used, the risk is higher than in conventional transplantation, depending on the
details of the conditioning (Olsson et al 2013).
The central problem of allogeneic transplantation is GVHD (Apperley and Masszi 2012). The
graft contains abundantly T-lymphocytes and natural killer (NK)-cells which can induce a
reaction against the tissues of the recipient. The onset of acute GVHD is usually during the
first few weeks after the transplantation.  Its most typical features are rash, diarrhea,
abdominal pain, and liver injury manifested as an increase in the serum levels of bilirubin and
transaminases. There are other less common manifestations including lung complications.
Also endothelium has been regarded as a target of acute GVHD; this links GVHD to
microangiopathic complications which are a relatively common cause of morbidity and
mortality after allogeneic transplantation (Tichelli and Gratwohl 2008). The incidence of
acute GVHD is approximately 20-40% if the donor is a matching sibling, and higher with
other types of donor (Ruutu et al 2000, Apperley and Masszi 2012).
In contrast to acute GVHD, the manifestations of chronic GVHD often resemble those of
autoimmune diseases, but little is known about the pathophysiology.  Chronic GVHD appears
usually after several months from the transplantation (Lee and Flowers 2008).  Most frequent
manifestations are skin dryness and sclerodermatic skin, dry mouth and mucositis, and dry
eyes. Other manifestations include liver injury, mainly affecting small bile ducts, and
malabsorption, as well as restrictive and particularly obstructive lung problems, the latter
manifesting as obstructive bronchiolitis.  Long-term atherosclerotic cardiovascular problems
bear a connection to chronic GVHD (Tichelli and Gratwohl 2008).
Approximately half of allogeneic transplant patients develop chronic GVHD, depending on
the  details  of  the  transplantation  procedure.  For  example  T-cell  depletion  and  the  usage  of
anti-thymocyte globulin (ATG) decrease the risk of GVHD. On the other hand, higher degree
of HLA-mismatch or unrelated donor, as well as peripheral blood stem cell (PBSC)-graft
increase the risk of GVHD (Mohty et al 2003, Apperley and Masszi 2012, Baron et al 2012).
.
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Prophylaxis and treatment of GVHD consist of immunosuppressive drugs (Ruutu et al 2014).
The most important drugs are calcineurin inhibitors, methotrexate, mycophenolate mofetil,
corticosteroids and ATG. Other forms of treatment used are various monoclonal antibodies,
mTOR inhibitors, extracorporeal photopheresis and mesenchymal stem cells. Although a
large proportion of patients respond to treatment, GVHD is still, together with infections, the
most important cause of mortality in allogeneic transplantation (Apperley and Masszi 2012).
Infections are an important cause of morbidity and mortality (Rovira et al 2012).  The
cytotoxic conditioning and the immunological effects of the graft destroy the immunological
system of the recipient. The rebuilding of the immunological system by cells from the graft
takes several months; the immunological competence has usually mainly recovered by one
year after the transplantation (Fujimaki et  al 2001, Seggewiss and Einsele 2010). Chronic
GVHD delays the recovery (Rovira et al 2012).  Susceptibility to infections is most marked
during  the  first  months  after  the  transplantation.  Both  bacteria,  viruses  and  fungi  can  cause
severe infections. The risk of pneumonia caused by Pneumocystis jiroveci is high but can be
prevented with prophylaxis. Of viruses, the most important causative agent is
cytomegalovirus. Epstein-Barr virus is also a frequent problem.
Allogeneic transplant patients need intensive follow-up and treatment during the first months
and up to a year after the transplantation, but after the recovery of the immunological system
all prophylactic treatment can often be discontinued.
Other important complications of allogeneic stem cell transplantation are veno-occlusive
disease of the liver (VOD, also called sinusoidal obstruction syndrome, SOS) and
transplantation-associated microangiopathy (TAM) (Ruutu et  al 2007, Coppell et  al 2010,
Carreras 2012).  In both the pathogenesis is based on injury of small blood vessels. Other less
common syndromes belonging to the same group are diffuse alveolar hemorrhage and general
capillary leak syndrome (Carreras 2012). In VOD, injury of endothelium in sinusoidal vessels
of the liver leads to obstruction of the sinusoids manifesting as enlarging liver with right
upper abdomen pain, icterus, fluid retention, and ascites. TAM manifestations include
generalized microangiopathy with fragmentation hemolysis, consumption-based
thrombocytopenia,  and  anemia,  which  can  lead  to  multiorgan  failure.  VOD  is  mainly  a
complication of the first month after the transplantation; the onset of TAM is usually during
the first hundred days. In both of these complications the mortality is high, although the
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situation has been improving especially in VOD due to development in treatment (Coppell et
al 2010, Carreras 2012).
Idiopathic pneumonitis syndrome (IPS) comprises a group of disorders that result in
interstitial pneumonitis and/or widespread alveolar injury (Clark et  al 1993).  IPS was an
important cause of morbidity and mortality in patients undergoing HSCT especially in the
early years of transplantations.  In recent years the incidence has somewhat fallen due to
developing transplantation techniques (regimens not including TBI, RIC) (Panoskaltsis-
Mortari et al 2011, Carreras 2012), but IPS is still a significant and feared complication.
The immune reconstitution after autologous stem cell transplantation occurs in general at a
faster tempo than in allogeneic HSCT, although variation according to underlying disease has
been reported (Damiani et al 2003, Laurenti et al 2004, Szodoray et al 2012).
2.2. Iron metabolism
2.2.1. Iron in the human body
The total amount of iron in the body in men and women is approximately 50 and 40 mg/kg
body weight, respectively. About 70% of the iron is found in red blood cell hemoglobin, ten
percent in myoglobin, less than one per cent in enzymes, and about one fifth as storage iron,
as ferritin and hemosiderin particularly in the liver, spleen and bone marrow (Muñoz et al
2009). The daily intake of iron in an ordinary diet is 15–20 mg. In normal conditions 1-2 mg
of iron is absorbed from the diet through the duodenum and is bound by transferrin, forming
diferric transferrin. The majority of transferrin-bound iron comes from senescent red blood
cells and is re-utilized for erythropoiesis in the bone marrow, approximately 20 mg of iron
daily (Shenoy et al 2014). Iron absorption is well regulated at the mucosal level (Fleming and
Ponka 2012).  There is no system to actively remove iron. Iron is passively exported out of
the body only by the shedding of the intestinal epithelium (approximately 1 mg/day) or
menstrual bleeding (1 mg/day) (Muñoz et al 2009). Therefore, systemic iron homeostasis is
strictly controlled at the level of absorption by hormonal signals in response to the iron load
(Ganz 2013, Shenoy et al 2014) (Figure 2).
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2.2.2. Mechanisms of iron regulation
Hepcidin, a small peptide produced by the liver, is a central molecule that regulates iron
metabolism (Krause et al 2000, Park et al 2001).  It has been found to be a key regulator of
the entry of iron into the circulation in mammals, including humans (Ganz 2013, Kautz and
Nemeth 2014). The hepatic expression of hepcidin can be upregulated by at least two
signals: iron loading  (Krause et al 2000, Park et  al 2001, Pigeon et  al 2001, Nemeth et  al
2004a, Nemeth et  al 2004b, Kawabata et  al 2007, Kanda et  al 2011),  and inflammatory
Figure 2. Regulation of iron metabolism.
Hepcidin regulation by erythropoiesis and its effects on iron efflux from cells involved in iron
metabolism. Hepcidin plays a central role in the maintenance of iron homeostasis and regulation of
plasma iron concentrations by controlling ferroportin concentrations on iron-exporting cells,
including duodenal enterocytes, recycling macrophages of the spleen and liver, and hepatocytes
(involved in iron storage). The bone marrow has the highest iron requirements for hemoglobin
synthesis, and thus, increased erythropoietic activity suppresses hepcidin production. Several
potential candidate erythroid regulators of hepcidin (e.g., GDF15 and TWSG1) have been reported.
Recently, a non-disease-specific mechanism has been proposed (e.g., ERFE= erythroferrone). EPO=
erythropoietin; Fe= iron; TWSG1= twisted gastrulation 1.   Reprinted and adapted by permission
from The American Society of Hematology: Shenoy et al, Blood 2014; 124(6):874.
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stimuli, including interleukin-6 (IL-6), IL-17, oncostatin M  (Nemeth et al 2004a, Nemeth et
al 2004b, Lee et  al 2005, Kawabata et al 2007, Kanda et al 2009, Kanda et al 2011) and
lipopolysaccharide (Lee et  al 2004). Hepcidin decreases iron absorption from the intestine
and blocks its release from iron stores by downregulating the expression of the cellular iron
exporter ferroportin (Nemeth et  al 2004a, Nemeth et  al 2004b, Kautz and Nemeth 2014),
thereby maintaining circulating iron levels within the normal range.
Hepcidin can be downregulated by erythropoiesis-associated factors (Kattamis et  al 2006,
Kanda et al 2008), possibly including  growth differentiation factor-15 (GDF) and a recently
identified hepcidin regulator, erythroferrone (Kautz et al 2014). The mechanisms of hepcidin
suppression are not fully understood, and may be disease specific (Shenoy et al 2014).
Hepcidin expression is markedly decreased in contexts in which erythropoiesis is increased,
such as phlebotomy, hemolysis, and administration of erythropoietin.  In hematopoietic stem
cell transplantation, the serum hepcidin level was shown to peak one week after HSCT,
during the deepest bone marrow depression, followed by a gradual decrease parallel with
increasing reticulocyte counts (Kanda et  al 2011). Erythropoietic activity has a greater
influence on hepcidin expression than body iron status does (Kattamis et al 2006, Jones et al
2015).
Hepcidin deficiency causes iron overload in hereditary hemochromatosis and diseases with
ineffective erythropoiesis (Ganz and Nemeth 2012a). Mice deficient in transferrin exhibit
anemia and a paradoxical iron overload attributed to hepcidin deficiency (Bartnikas et al
2011). Similar findings in zebrafish have been reported by Fraenkel et al (2009). These
studies indicate that transferrin may have an essential role as a regulator of hepcidin
expression.
Several studies have shown that serum hepcidin levels are inappropriately low compared with
the levels of iron load in some MDS patients, in line with observations in beta-thalassemia
(Winder et al 2008, Murphy et al 2009), and high levels of GDF-15 with a suppressive effect
on hepcidin (Tanno et al 2007) were reported in patients with refractory anemia with ringed
sideroblasts  (Ramirez et al 2009).
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Increased  circulating hepcidin contributes to anemia in inflammatory disorders, chronic renal
disease, and cancer (Ganz and Nemeth 2012a).  Anemia of inflammation is caused by the
upregulation of hepcidin by IL-6 leading to decreased circulating iron levels. The high serum
hepcidin levels frequently observed in patients with myeloma and Hodgkin’s lymphoma,
related to IL-6 upregulation, may partly contribute to the anemia of these patients (Sharma et
al 2008, Ganz and Nemeth 2009, Hohaus et al 2010).
2.3. Iron overload
In the treatment of malignant hematological diseases such as MDS and acute leukemia,
multiple blood transfusions are required owing to ineffective erythropoiesis caused by the
disease or to cytotoxic chemotherapy. However, iron overload is observed in some MDS
patients without a history of transfusion (Cortelezzi et al 2000). Humoral factors with a
suppressive effect on hepcidin may also play a role in iron overload (Kanda et al 2008), e.g.
erythroferrone, as suggested by Kautz et al (2014).
2.3.1. Red blood cell (RBC) transfusions
RBC  transfusions  contribute  strongly  to  the  development  of  iron  overload  in  patients  with
hematological malignancies as well as transplantation patients. A widely used threshold for
RBC transfusion  is  the  hemoglobin  level  of  80  g/l,  in  case  there  are  no  signs  of  anemia  or
clinically significant cardiac impairment (Pawson 2012). Although red cell transfusions are
necessary to improve anemia-associated symptoms, multiple transfusions lead to iron
accumulation because of the lack of an active iron export system. One red cell unit contains
approximately 200-250 mg of heme iron, corresponding to the amount of iron normally
absorbed in 6 months (Shander and Sazama 2010).
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2.3.2. Evaluation of iron overload
2.3.2.1. RBC units
The  simplest  way  to  evaluate  iron  burden  is  the  number  of  RBC  units  given.  As  one  unit
provides 200-250 mg of iron, a significant (4000-5000 mg) iron overload is reached with 20
transfused units.
2.3.2.2. Ferritin
Ferritin  is  the  main  storage  form  of  iron.  A  proportion  of  ferritin  is  released  into  the
circulation, and its serum levels, controlled by cellular iron status, correlate well with the
body’s iron stores. However, because the serum level is also increased in patients with
inflammation, it does not necessarily accurately represent the body iron load status in specific
conditions, such as infection and autoimmune diseases (Lee and Means 1995, Olivé and
Juncà 1996).
2.3.2.3. Liver iron content (LIC)
Hepatic iron content is considered to be a reliable indicator of total body iron stores
(Angelucci et al 2000). Measuring the iron content of biopsy specimens from the liver has
been a ‘gold standard’ for the evaluation of body iron overload (Emond et al 1999).
LIC is usually reported in μg/g (mg/g) dry weight with normal values 400-2200 μg/g (0.4-2.2
mg/g) in men, and 100-1600 μg/g (0.1-1.6 mg/g) in women (Batts 2007). Iron overload is
considered to be  severe when  LIC is  >7 mg/g (Tichelli 2012), or 10 mg/g (Batts 2007).
In allogeneic HSCT a histological evaluation of liver specimens provides useful information
to differentiate iron overload from other causes of hepatic dysfunction such as GVHD and
hepatic veno-occlusive disease (VOD). However, because iron distribution in the liver is
often heterogeneous, multiple biopsies are required to accurately determine the liver iron
concentration (Emond et  al 1999). Furthermore, hematologic patients in the peritransplant
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period are often thrombocytopenic and at a high risk of bleeding, and therefore a non-
invasive evaluation of iron levels is preferred in the transplant setting.
2.3.2.4. Magnetic imaging
Using the paramagnetic properties of storage iron, the superconducting quantum interference
device (SQUID) biosusceptometer was developed to measure iron levels (Sheth 2003). Iron
content measured by this method has shown a good correlation with liver iron content
measured by biopsy, but SQUID is available in only a few centers worldwide. Quantitative
magnetic resonance imaging (MRI) enables the measurement of iron distribution and its
averaged concentration for the entire liver and heart and has become a widely available
modality for performing iron measurements (Anderson et  al 2004,  St  Pierre et  al 2005,
Tanner et al 2006, Di Tucci et al 2008).
2.4. Iron toxicity
Highly reactive oxygen species (ROS) produced by free ferrous (Fe2+) iron through the
Fenton reaction are toxic to various internal organs.  ROS oxidize lipids, proteins, and nucleic
acids, resulting in premature apoptosis, cell death, and tissue and organ damage (Shenoy et al
2014). Under normal conditions, toxic reactions caused by free iron are prevented by
circulating transferrin forming a compound with ferric (Fe3+) iron.
Iron bound to transferrin is utilized in the bone marrow or transferred to the liver, where the
cells express transferrin receptors and can take up transferrin by receptor-mediated
endocytosis. In iron-overloaded conditions, such as primary or secondary hemochromatosis,
plasma non-transferrin-bound iron (NTBI) levels increase to a measurable level because
transferrin is almost or fully saturated with iron (von Bonsdorff et al 2002). The iron content
of parenchymal cells in organs such as the liver, pancreas, heart and gonads increases due to
uptake of the NTBI, potentially leading to irreversible organ damage and organ failure
(Pietrangelo 2010).
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There is evidence to indicate that iron overload impedes erythropoiesis. Iron overload inhibits
burst-forming unit (BFU-E) colony formation and erythroblast differentiation of both murine
and human hematopoietic progenitors in vitro, and cells exposed to excess iron exhibit
dysplastic changes with increased intracellular ROS and decreased bcl2 (anti-apoptotic gene)
expression (Taoka et  al 2012). Erythroid progenitors seem to be more susceptible to iron
overload than myeloid progenitors (Hartmann et al 2013). Iron chelation has been shown to
result in improved hemoglobin levels and reduced RBC transfusion requirements (Badawi et
al 2010, Oliva et  al 2010). In MDS,  iron chelation improves blocked differentiation of
hematopoietic cells and possibly reduces the risk of transformation to leukemia (Shenoy et al
2014). It is reasonable to expect that iron depletion is beneficial for erythropoiesis in iron
overload states (Camaschella et al 2007).
2.4.1. Iron and infections
Iron  is  a  necessary  nutrient  for  the  proliferation  of  bacteria  and  fungi,  especially  in  a  form
easily accessible to the micro-organisms and not tightly bound to transferrin. They have
developed several methods to obtain iron from the host, such as siderophores that acquire
iron either from host proteins or from low-molecular-mass iron compounds (Weinberg 2009).
In vitro, bacterial growth is faster after the addition of iron and the growth is slower after iron
deprivation using an iron chelator (Weinberg 2009). An association between iron overload
and bacterial or fungal infections has been demonstrated in hereditary and secondary
hemochromatosis (Evens et  al 2004, Khan et  al 2007). In HSCT patients, increased
pretransplant serum ferritin concentration or liver iron overload have been shown to be
associated with an increased risk of bacterial or fungal infections (Altes et al 2004, Schaible
and Kaufmann 2004, Altes et al 2007). Iron overload also has a negative impact on the
functions of cells such as monocytes, neutrophils, macrophages, and natural killer cells that
normally contribute to immunity to infections (Blijlevens et al 2000). Iron overload may also
exacerbate the consequences of mucosal damage caused by chemotherapeutic agents and
irradiation, allowing bacterial organisms to enter the circulation (Blijlevens et al 2000, Altes
et al 2007).
27
2.4.2. Non-transferrin-bound iron (NTBI)
A central feature of NTBI is that it is not bound to the principal iron carrier transferrin. Such
iron can be loosely bound to serum albumin, citrate and other undefined negatively charged
ligands; because of its cationic nature iron cannot exist in absolutely free form (Breuer and
Cabantchik 2001, Patel and Ramavataram 2012). The characteristic feature of such iron is
that it retains its ability to catalyze the formation of ROS (Nilsson et al 2002).
Various terms have been used to address the same overlapping fraction of plasma iron: NTBI
(Breuer and Cabantchik 2001), free iron (Nilsson et al 2002), catalytic iron pool (Halliwell
and Gutteridge 1990, Kakhlon and Cabantchik 2002, Kruszewski 2003),  and labile iron
(Breuer and Cabantchik 2001). Based on the chelating properties of NTBI, different terms
have been used: bleomycin detectable iron (BDI), deferoxamine chelatable iron (DCI),
mobilizer dependent chelatable iron (MDCI), and bathophenantroline detectable iron (Breuer
and Cabantchik 2001, von Bonsdorff,  et  al 2002, Patel and Ramavataram 2012). DCI has
been later used by the same investigators to indicate the NTBI forms that can readily be
chelated with deferoxamine without the assistance of mobilizers (Esposito et al 2003). MDCI
has  been  used  to  indicate  the  NTBI  forms which  can  be  detected  only  after  the  action  of  a
mobilizer such as oxalate or nitrilotriacetic acid (NTA) (Anderson 1999).
Bathophenantroline detectable iron is applicable for NTBI forms which are directly chelated
by the chromogenic chelator BPS (Nilsson et al 2002).   Common for all these terms is that
they refer to iron bound essentially to molecules other than transferrin.
Methods to measure the concentration of NTBI or any form of free iron have been developed
and some are listed in Table 1.
28
Table 1.  Assays for measurement of serum NTBI
Assay type Quantitation of iron Reference
1. Chelation of NTBI
Chelation of NTBI with EDTA,
ultrafiltration of complex
Colorimetric Hershko et al 1978
Chelation of NTBI with NTA,
ultrafiltration of complex
HPLC Singh et al 1990, Porter et al
1996
Colorimetric using
bathophenantroline chromogen
Zhang et al 1995, Gosriwatana et
al 1999
Atomic absorption
spectrophotometry
Dürken et al 1997, Gosriwatana
et al 1999, Jakeman et al 2001
Chelation of NTBI with oxalate,
transfer of oxalate to
immobilized desferrioxamine
Fluorescence using metallosensor
calcein
Breuer et al 2000b
Chelation of NTBI with
desferrioxamine
Chelation of NTBI with
hexadentate
hydroxypyridinone-based beads
Fluorescence quenching of
fluorescein-desferrioxamine
probe
Beads containing both fluorescent
and chelating moieties, flow
cytometry
Breuer et al 2001, Breuer and
Cabantchik 2001
Ma et al 2014
2. Biochemical reactions caused by NTBI
Bleomycin assay. Ferrous iron
complexed with bleomycin
causes DNA degradation,
degradation products are
measured
Thiobarbituric acid reaction,
spectrophotometry
Gutteridge et al 1981, Gutteridge
and Hou 1986, Evans and
Halliwell 1994
Ethidium-binding assay Burkitt et al 2001
Activation of iron-sulphur
cluster of aconitase
Enzymatic Mumby et al 1998
Reprinted and adapted by permission from von Bonsdorff (2003).
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2.4.3. Sources and status of NTBI in the circulation
The saturation of transferrin is about 30% at the normal serum iron level (approximately 20
μmol/l).  Transferrin-bound iron is the only major form of non-heme iron present in plasma.
In normal physiological conditions the transferrin concentration is sufficient for binding
significantly greater doses of free iron and ensuring its absence in the internal milieu. This is
the reason why NTBI is usually undetectable by most methods, and if found, its concentration
does not exceed 1 μmol/l (Anderson 1999, Patel and Ramavataram 2012).  In iron overload
syndromes, such as thalassemia and hemochromatosis, the transferrin binding capacity is not
sufficient and free iron is formed (Hershko et al 1978, Graham et al 1979, Batey et al 1980,
Aruoma et al 1988, Porter et al 1996, Loréal et al 2000). The explanation for the existence of
low concentrations of free iron even in case of low transferrin saturation is unclear
(Gosriwatana et al 1999, Breuer et al 2000b, Loréal et al 2000).
In hemolytic anemia increased endogenous inflow of iron due to excessive hemolysis and/ or
compensatory blood transfusions may cause high saturation of transferrin leading to the
appearance of NTBI (Fibach and Rachmilewitz 2008, Ozment et  al 2013).  NTBI  has  also
been demonstrated in diabetes mellitus (Lee et al 2006). It has been suggested that glycated
proteins, the concentrations of which are high in diabetics, do not only bind iron and copper
with higher affinity but also have a tendency to extract iron from the traditional iron carriers.
In cancer patients undergoing chemotherapy the reasons for the presence of NTBI are
temporary shut-down of bone marrow function and associated reduced demand of iron. Other
clinical conditions in which the presence of NTBI has been indicated are end-stage kidney
disease patients treated with dialysis (Prakash et al 2005), alcoholism (De Feo et  al 2001),
myelodysplastic syndromes (Cortelezzi et al 2000, Mahesh et al 2008) and beta-thalassemia
(al-Refaie et  al 1992). In atransferrinemia or hypotransferrinemia it is pertinent that all or
most of the plasma iron exists as NTBI. In the absence of transferrin, NTBI levels up to 20
μmol/l have been reported, whereas in the presence of insufficient transferrin concentrations
the levels were found to be less than 10 μmol/l (Anderson 1999).
Various forms of NTBI may coexist depending on the degree and cause of iron overload.
Clinically it has been proven that the efficacy of different iron chelators vary in various
clinical conditions which indirectly supports the heterogeneity of NTBI. Careful segregation
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of various isoforms of NTBI is essential  in establishing the role of individual isoforms in
specific pathological condition (Patel and Ramavataram 2012).
3. IRON AND HSCT
3.1. Causes and impact of iron overload in HSCT
Iron overload is frequently observed in patients with hematologic diseases before and after
allogeneic stem cell transplantation (Sivgin and Eser 2013). Many transplant patients have a
history of multiple red cell transfusions. Blood transfusions are often needed during the
transplantation  treatment,  and  some patients  need  transfusions  for  a  significant  period  after
the transplantation.  In some diseases, such as thalassemia and MDS (Cortelezzi et al 2000),
erratic absorption of iron may contribute to the development of iron overload.
In the peritransplant period, in addition to iron accumulation due to multiple red cell
transfusions, bone marrow suppression caused by chemotherapeutic agents and irradiation
substantially increases NTBI levels because erythropoiesis is the main route of utilization of
circulating iron (de Witte 2008). Through the generation of ROS, increased NTBI may
exacerbate organ and mucosal damage caused by chemotherapeutic agents and irradiation
(Figure 2).
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Figure 2. Possible mechanisms and interventions in iron-induced HSCT-toxicity.
GVHD = graft-versus-host disease, IPS = idiopathic pneumonitis syndrome, SOS = sinusoidal
obstruction syndrome. Reprinted and adapted by permission from Nature Publishing Group: Evens
et al, Bone Marrow Transplant, 2004; 34: 561-571.
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The transplantation procedure affects the distribution of iron in the body. The conditioning
treatment before the transplantation causes cessation of red cell production and reduction in
the utilization of iron. Conditioning can also reduce the production of the main iron-carrying
protein, transferrin, in the liver, and injury of liver cells may cause release of storage iron. In
a large proportion of transplant patients the transferrin saturation reaches levels over 80%
during the bone marrow depression (Altès et  al 2002). These effects may lead to the
appearance of NTBI.
The impact of iron overload for the outcome of transplantation has been evaluated in a
number of studies. In most of them ferritin has been used as a surrogate marker for iron load.
Generally iron overload has been found to have a negative impact on the outcome. Several
studies have shown that elevated pre-transplantation serum ferritin levels are associated with
impaired overall  (Altès et al 2002, Armand et al 2007, Kim et al 2008, Pullarkat et al 2008,
Kataoka et al 2009, Mahindra et al 2009, Bazuaye et al 2012) or  relapse-free (Armand et al
2007, Mahindra et al 2009) survival, and/or increased non-relapse mortality (Altès et al 2002,
Pullarkat et  al 2008, Kataoka et  al 2009, Mahindra et  al 2009) after allogeneic
transplantation.  Bazuaye et al (2012) have shown that also other iron parameters, in addition
to  ferritin, especially soluble transferrin receptor, have similar and at least as good predictive
value for transplantation outcome as ferritin. Higher than median soluble transferrin receptor
levels, as well as lower than median ferritin levels, predicted better overall survival (OS).
The studies showing impaired outcome after HSCT in patients with iron overload have been
based on ferritin as a surrogate marker of iron. However, ferritin increases not only by iron
loading but also by inflammation caused by GVHD and infection, and that  can lead to a wide
difference  between the ferritin status and the actual iron load (Jastaniah et al 2008).
Therefore, considerable effort has been invested to evaluate the iron load and its distribution
in the main organs, particularly the liver and heart (Anderson 1999, Emond et al 1999, Sheth
2003, St Pierre et al 2005, Tanner et al 2006, Di Tucci et al 2008).  The causal relationship
between iron overload and adverse outcomes remains unclear and needs further investigation.
In fact, Trottier et al (2013), using liver magnetic resonance imaging (R2-MRI) to quantify
liver iron content, did not find any association between pretransplant iron overload and
allogeneic stem cell transplantation outcomes. The same results came out in the meta-analysis
by Armand  et al (2014), where pre-transplant iron overload (>7 mg/g dry weight), assessed
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by MRI estimation of LIC, was not associated with a significant increase in mortality and, as
such, not a strong prognostic factor for OS.
3.1.1. Iron and hepatic complications
Liver  being  one  of  the  organs  in  which  iron  preferentially  accumulates,  iron  overload  may
particularly trigger and exacerbate hepatic injury after a conditioning regimen.
Liver enzyme elevations are very common in the first months after HSCT, and are also found
in long-term survivors to varying degrees. The etiology of these liver abnormalities is
multifactorial and may be related to hepatitis, graft-versus-host disease, or iron overload
(Tomás et al 2000, de Witte 2008). An association between hepatic VOD and iron overload
has been suggested by several studies (Morado et al 2000, Armand et al 2007, Maradei et al
2009).
Liver biopsies have shown that hemosiderosis occurs in most patients receiving
chemotherapy with or without HSCT (Iqbal et al 1996), and hepatic iron and serum ferritin
levels may be raised for several years after transplantation (Butt and Clark 2003). More than
80% of HSCT patients may be iron-overloaded at one year or later after the transplantation,
as indicated by their serum ferritin levels (McKay et al 1996). Serum aminotransferase levels
may be increased in  association with iron overload for at least three years after HSCT,
though the significance of this is not clear (Harrison et al 1996). Liver enzyme abnormalities
caused by iron overload can mimic GVHD or hepatitis (Kamble et al 2006). An assessment
of the cause of the liver enzyme abnormalities and iron loading status is necessary to avoid
unnecessary treatment with immunosuppressive agents for chronic GVHD, which will expose
patients to a higher risk of infection.
3.1.2. Iron and graft-versus-host disease
In acute GVHD,  proinflammatory cytokines released from damaged tissues activate host
antigen-presenting cells, enhancing the cross-presentation of minor antigens to donor T-cells
and activating them (Blazar et  al 2012). Therefore, tissue damage exacerbated by iron
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overload might worsen acute GVHD.  Elevated ferritin levels have been found to be
associated with the incidence of acute GVHD or early transplant mortality (Platzbecker et al
2008, Pullarkat et al 2008).
Ferritin can sequester and store large amounts of iron, and may exert suppressive effects on
the immune system (Recalcati et al 2008). Ferritin is composed of heavy chain subunits (H-
ferritin) and light chain subunits (L-ferritin), both of which are regulated by post-
transcriptional, iron-dependent machinery. Several studies have shown that ferritin can
suppress the proliferation of T-cells in response to mitogens, impair the maturation of B-cells
and inhibit the proliferation of myeloid precursor cells (Matzner et al 1979, Broxmeyer et al
1991, Cardier et  al 1995). The immunosuppressive effect of ferritin has been proposed to
been mediated by IL-10 (Gray et  al 2001). It is suggested that H-ferritin induces the
differentiation of dendritic cells, which stimulate  IL-10 production  from regulatory T-cells
(Gray et al 2002).
 Elevated pretransplant ferritin levels have been found to associate with a decreased incidence
of chronic GVHD (Mahindra et  al 2009). This may be related to the suppressive effect of
ferritin on adaptive immune responses. However, these observations are based on ferritin
levels and there is no clear evidence of the association of iron overload and acute or chronic
GVHD (Majhail et al 2008, Trottier et al 2013).
3.1.3. Iron and infections
Iron  is  an  important  nutrient  for  bacteria  and  fungi,  and  therefore  excess  iron  may enhance
their proliferation (Weinberg 1978).  In the HSCT setting, the ability of NTBI to enhance the
proliferation of Staphylococcus epidermidis was  shown  in  an in vitro study by our group
using the serum of patients undergoing HSCT (von Bonsdorff et al 2003, von Bonsdorff et al
2004). Consequently, the high levels of NTBI observed in the post-transplant period may be a
good environment for microorganisms to proliferate.
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3.1.4. Iron and other transplant-related complications
In a study using T2-MRI, abnormally high iron levels were detected in the pancreas and
pituitary gland in 40 and 55% of the patients, respectively (Au et al 2007). In 40 and 70% of
the patients the pancreatic and pituitary function was found to be abnormal.
There is evidence to suggest that iron-induced ROS formation may contribute to the
development of IPS. Free radicals may cause endothelial injury, both by direct cell damage
and indirectly by inducing the expression of cytokines that amplify IPS, resulting in acute
lung injury and pulmonary fibrosis (Crouch 1990, Balla et al 1993, Evens et al 2004).
3.2. Treatment of iron overload
Phlebotomy is the preferred way to reduce iron overload after the transplantation, if feasible.
However, many patients have prolonged anemia which prevents the use of this method. Data
of the utility of iron chelation therapy in stem cell transplantation is very limited.  It has been
shown, however, that patients with beta-thalassemia major who received regular chelation
therapy in the pretransplantation period have improved outcomes after HSCT (Lucarelli and
Gaziev 2008). Retrospective studies have also suggested that iron chelation in patients with
MDS reduces morbidity (Takatoku et al 2007)  and improves survival (Leitch 2007, Rose et
al 2010).  In a retrospective study by Lee et al (2009), patients with ferritin levels over 1000
ng/ml had a worse survival and higher transplant related mortality than those with lower
ferritin levels. However, among patients with high ferritin levels who had had pretransplant
iron chelation therapy and reached levels lower than 1000 ng/ml before the transplantation,
the survival and transplant related mortality were not significantly different from the patients
with initially low ferritin.  One small study has reported that deferoxamine therapy after
HSCT reduced serum ferritin levels faster than phlebotomy and was well tolerated without
evidence of graft failure (Li et al 2000).
Currently there are two oral iron chelators in clinical use, deferiprone and deferasirox. Severe
agranulocytosis can occur with the use of deferiprone, and it has not been investigated in the
HSCT setting (Pullarkat 2010). The efficacy and safety of deferasirox have been shown in
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thalassemia-patients (Taher et al 2012, Taher et al 2014). In a retrospective study, the OS of
HSCT patients with iron overload was significantly better with pretransplantation use of
deferasirox than that of the non-chelated patients (Sivgin et al 2013). In the first  prospective
post-transplantation study in HSCT patients with transfusional iron overload, the use of
deferasirox  for one year starting from 6 months after transplantation  provided a significant
reduction in serum ferritin and liver iron concentration, with  mild or moderate adverse
effects (Vallejo et al 2014).
In the light of the literature, iron chelation therapy before the transplantation, if logistically
feasible, or after the transplantation may improve transplantation outcomes, but this remains
to be carefully investigated.
4. TRANSFERRIN AND APOTRANSFERRIN
Transferrin is one of the most abundant proteins in human plasma, with an approximate
concentration of about 2-3 g/l (von Bonsdorff et al 2013).  It is the major iron transporting
protein in the blood stream, and it plays an important role in the iron metabolism of the
human body (Anderson and Vulpe 2009). Transferrin carries iron particularly for red cell
production which requires high amounts of iron for heme synthesis, as well as to other
rapidly dividing cells. It also sequesters iron released from the duodenal cells during dietary
absorption and from macrophages which engulf senescent blood cells.  Transferrin is of
utmost importance in the transportation of iron; however, the 3-4 mg of transferrin-bound
iron comprises only about 0.1% of the total body iron of which 60-70% is found in the red
blood cell compartment and the rest in other iron proteins, such as ferritin and myoglobin.
Transferrin-iron turnover is highly dynamic and about 30 mg iron is transported daily to the
cells. Other iron binding proteins such as ferritin and hemosiderin are the intracellular iron
storage proteins, which can store considerably higher amounts of iron per molecule (e.g.
ferritin up to 4500 iron atoms) than transferrin  with the maximum of two iron atoms (Sargent
et al 2005).
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Under normal physiological conditions, practically all iron in plasma is bound to transferrin,
and the transferrin iron saturation is about 30%, constantly offering surplus of iron binding
sites. Transferrin keeps iron in a form which makes it suitably accessible to the cells requiring
iron. Under physiological pH iron ions easily form non-soluble hydroxide complexes;
transferrin retains a soluble form of iron. By binding iron transferrin prevents the free radical
reactions caused by free iron. An additional advantage is that iron bound to transferrin is not
accessible to microorganisms (Weinberg 1999).
Transferrin is synthesized mainly in the liver. It is one of the acute phase proteins with
suppressed production in inflammation. On the other hand, transferrin levels can be elevated,
for example during pregnancy.  As described above, in some disease or treatment conditions
the iron binding capacity of transferrin is overwhelmed and the saturation level is exceeded,
leading to the formation of non-transferrin-bound iron in the blood stream, which can result
in iron depositions in non-hematological cells and lead to organ damage (Shander et al 2009,
Hershko 2010).
The receptor-mediated endocytosis whereby transferrin-bound iron is taken up by cells is a
well described process (Richardson and Ponka 1997, Cheng and Walz 2007). Transferrin
carrying iron is bound to transferrin receptors on the cell surfaces. This transferrin receptor
complex is internalized and iron is released through protonation, which lowers the pH,
whereafter iron-free apotransferrin is recirculated to the blood stream. The half-life of
transferrin is approximately  8-9 days (Katz 1961).
Of the two transferrin receptors, transferrin receptor 1 is the better characterized  (Aisen
2004).  It binds transferrin with high affinity. It has a much higher affinity for the iron-
saturated form of transferrin than for transferrin carrying only one iron atom or for iron-free
apotransferrin (Qian et al 2002). The transferrin receptor can be expressed in abundance, for
example, on the surface of erythroid precursors with a high requirement of iron (Ponka et al
1998), and on other actively dividing cells, including cancer cells  (Daniels et al 2006). A
proportion of these transferrin receptors is soluble and circulating in the blood stream.  As the
concentration  of  soluble  transferrin  receptors  is  in  proportion  to  the  expression  on  the  cell
surface, the receptor level is used as a diagnostic tool for measuring iron deficiency anemia,
where a high receptor expression is typical.
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4.1. Biochemistry
Transferrin is classified as a beta-1 globulin. The transferrin molecule is a single polypeptide
chain containing 679 amino acid residues (MacGillivray et al 1983). It is organized into two
homologous lobes of about 330 amino acid residues, called the N- and the C-lobe (Figure 3).
The lobes are linked by a short flexible spacer peptide and each lobe contains two dissimilar
domains divided by a cleft, which is the binding site for Fe3+ (Bailey et al 1988, Wang et al
1992). The synergistic binding of an anion, preferentially the carbonate molecule, is essential
for the iron binding. Transferrin is capable of binding several other metal ions, but with a
lower affinity (Harris and Aisen 1989).
Each molecule of transferrin can bind two Fe3+ ions. The four iron forms of transferrin are the
iron-free apotransferrin, the monoferric transferrin with iron in the C- or in the N-lobe,
respectively, and the diferric holotransferrin. The affinity of transferrin for iron at the
physiological pH of 7.4 is high (Harris and Aisen 1989). Upon binding of iron, the lobes
N-lobe
C-lobe
Figure 3. A ribbon diagram of a diferric rabbit serum transferrin molecule. Reprinted and adapted
by permission from von Bonsdorff (2003).
39
undergo a conformational transition from the apo structure with an open interdomain cleft to
a closed holo structure (Hirose 2000).
Transferrin is a glycoprotein and two N-linked oligosaccharides are found at the C-lobe at
asparagine residues Asn413 and Asn611. The carbohydrates constitute about 6% of the mass of
transferrin that has a molecular weight of 79750. The glycan chains are mainly biantennary
(85%) and triantennary (15%) complex type glycans (Spik et  al 1985, Fu and van Halbeek
1992).  The number of sialic acid residues per transferrin molecule is between 4 and 6. The
heterogeneity of the glycosylation is a determinant of the microheterogeneity of transferrin.
Glycosylation variants can occur in different diseases or states. For example, in patients
suffering from alcoholism, carbohydrate chains lacking two to four of the terminal
trisaccharides, comprising the negatively charged sialic acid  and the neutral N-
acetylglucosamine and galactoside, are common (Stibler 1991).  The presence of
carbohydrate-deficient transferrin can be used as a marker of alcoholism (Turpeinen et al
2001).  Another determinant of microheterogeneity is the genetic polymorphism. The most
common  variant  was  designated  TfC,  while  the  other  common  forms  are  TfB  and  TfD
(Kamboh and Ferrell 1987). Of at least 38 variants, only 4 occur with a frequency of  over
1%  (de Jong et al 1990). Attempts to establish a relationship between the transferrin variant,
serum transferrin concentration, and iron binding capacity have been inconclusive (Sikström
et al 1993).
4.2. Manufacture
Transferrin is not a widely used plasma protein, and the process for commercial
manufacturing has been set up only by some companies, whose aim is to provide transferrin
as a cell culture or biochemical reagent. Transferrin can be produced from human plasma,
and for this the widely used plasma fractionation procedures can be utilized as the basis.
Transferrin precipitates into fraction IV, subfraction IV4, in the Cohn crude ethanol
fractionation process for human plasma (Cohn and Strong 1946).  Fraction IV has been a
much used starting material to produce human transferrin as in many cases it is a surplus
fraction in commercial fractionation process and thus discarded. In the first descriptions of
large scale manufacturing of transferrin, precipitation, chromatographic and crystallization
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techniques were employed to obtain highly purified transferrin (Kistler et al 1960, Inman et
al 1961). Since then, the manufacturing methods have evolved and today they usually employ
generally used techniques of protein purification and downstream processing. Current
manufacturing processes aiming at clinical use include additional steps to achieve viral
safety.
The transferrin preparations obtained by the different processes vary in regard to iron form.
In some cases a process has been set up specifically to obtain iron saturated holotransferrin
(Inman et al 1961, Van Beveren and Pappenhagen 1987, Rolf et al 1997) and others for iron-
free apotransferrin (von Bonsdorff et al 2001, McCann et  al 2005, Ascione et al 2010).
Manufacturing methods can be or have been adopted so that a specific iron removal step or
addition step is added to the process to ensure that transferrin of the desired iron form is
obtained. A method for the production of transferrin was developed by the Finnish Red Cross
Blood Transfusion Service in the 1990s (von Bonsdorff et al 2001), and based on this method
a large scale  production process has since been set up by a pharmaceutical company
(Sanquin Plasma Products, The Netherlands).  After the protein purification has taken place,
transferrin-bound iron is removed by lowering the pH and adding the chelating agent EDTA
so that apotransferrin is obtained as the final product.  For this particular process, virus safety
validation studies show high reduction results: overall reduction of enveloped viruses is
>19log10, and in the nanofiltration step included in the process the reduction of non-
enveloped viruses hepatitis A virus (HAV) and canine parvovirus (CPV) is >5log10  (von
Bonsdorff et al 2013).
Transferrin has been presented in different formulations, for example a liquid 5%
weight/volume formulation in sodium chloride (von Bonsdorff et al 2001), or a freeze-dried
formulation in phosphate, sodium chloride and glycine  (Ascione et al 2010). The former has
been shown to be stable for up to 3 years when refrigerated (von Bonsdorff et al 2013),  the
latter  for at least 18 months at room temperature  (Ascione et al 2010). In addition to these
manufacturing processes which focus on large scale manufacturing of human transferrin from
plasma,  there  are  numerous  descriptions  of  small  laboratory  scale  purifications  schemes  to
obtain purified transferrin (Wu et  al 2008).  Many of these are described for recombinant
transferrin molecules. Transferrin has been expressed in a large variety of recombinant
systems, either as a full length molecule in mammalian baby hamster kidney (BHK) cells
(Mason et al 1993),  in microbial systems (Sargent et  al 2006, Mizutani et al 2010,
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Mukaiyama et al 2010),  and in plants (Brandsma et al 2010, Zhang et al 2010), or as N- and
C-terminal half-molecules in both eukaryotic expression systems (Funk et al 1990, Mason et
al 1996 Mason et  al 1997, Mason et al 2001), and prokaryotic systems  (Hoefkens  et  al
1996).  Such recombinant transferrin products have mainly been used in structural and
functional protein analyses. Only one recombinant transferrin product is commercially
available. This transferrin is a non-glycosylated (or partly O-glycosylated) form of transferrin
expressed in a yeast (Saccharomyces cerevisiae) (Keenan et al 2006, Finnis et al 2010).
Despite its abnormal glycosylation it is reported to have similar iron binding and transport
abilities as human plasma transferrin and it can be used as a cell culture agent. So far, there is
no description of its behavior  in man (Brandsma et al 2011).
4.3. Characterization
Currently, transferrin is not commercially available as a pharmaceutical, and therefore the
compendial pharmacopeia requirements available for other plasma protein therapeutics do not
exist. A number of methods have been used to measure the concentration and purity, iron
content, saturation and forms, as well as the iron binding capacity and biological activity (von
Bonsdorff et al 2013).
The most obvious methods for visually distinguishing the iron forms of transferrin are  the
distinct colors; holotransferrin has a dark red “rusty” color while apotransferrin is pale
yellowish or almost colorless. The colorimetric change can also be used as a tool to measure
the iron binding capacity of transferrin as the spectrometric absorption at 450-460 nm
changes when known amounts of ferric iron are added to a predetermined amount of
transferrin (von Bonsdorff et al 2013). Another commonly used method for determining the
transferrin iron form is polyacrylamine gel electrophoresis in urea, which is a good tool in
distinguishing all transferrin iron forms (Makey and Seal 1976, Evans and Williams 1980).
As transferrin does not have enzymatic or similar properties, its function can best be
established by its iron binding properties (Welch and Skinner 1989, von Bonsdorff et  al
2001), its ability to bind to transferrin receptors (Fuchs and Gessner 2002), and its ability to
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enhance in vitro growth of mammalian cells dependent on transferrin-bound iron for growth
(Keenan et al 2006, Ascione et al 2010).
4.4. Potential clinical applications
Potential uses of transferrin are substitution therapy in transferrin deficiency and the
utilization of its iron binding and regulatory properties in iron metabolism.  It has also been
used as a targeting molecule (von Bonsdorff et al 2013).
Due to the indispensable role of transferrin as an iron transport protein in plasma, patients
with a genetic deficiency of transferrin are radically dependent on substitution therapy with
human plasma transferrin. Hypotransferrinemia is a very rare hereditary disease and only a
very limited number of cases have been reported worldwide (Goya et al 1972, Hayashi et al
1993, Beutler et al 2000).  An ongoing clinical study by Sanquin investigates the treatment of
hypotransferrinemia with apotransferrin.
Transferrin has been studied in several animal disease models in which a redox-active iron is
considered to play a pathogenetic role (von Bonsdorff et  al 2013). Apotransferrin
administration was shown to effectively mitigate kidney injury in a mouse model of renal
ischemia/reperfusion (I/R) injury  (de Vries et al 2004). Apotransferrin reduced not only
extracellular redox-active iron but also intracellular generation of reactive oxygen species.
Subsequently, apotransferrin administration was studied in a porcine liver transplantation
model, which is associated with severe I/R injury and a high incidence of primary graft non-
function after transplantation. Apotransferrin was administered intravascularly to the
recipients together with other anti-inflammatory and hepatoprotective agents. This treatment
regimen remarkably protected ischemically damaged liver grafts against primary non-
function and promoted the recovery of graft function (Monbaliu et al 2009).
The increasing understanding  of the regulation of iron metabolism by hepcidin and the
accumulating evidence on the involvement of transferrin in the regulation of hepcidin
expression have given new insight into the possibilities of treating diseases with aberrant iron
metabolism by transferrin.
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It has been demonstrated that allogeneic stem cell transplantation is associated with liver iron
accumulation (Iqbal et al 1996, de Witte 2008). Studies in a mouse model of GVHD showed
that apotransferrin administration effectively  mitigated iron accumulation in the liver and
prevented liver injury and apoptosis (Bair et al 2009).  In a previous study it was
demonstrated that the hepatoprotective effect of transferrin was mediated by type 2
transferrin receptor, suggesting that transferrin may induce antiapoptotic signaling through
the type 2 receptor (Lesnikov et  al 2001).  Recent findings in a mouse model of beta-
thalassemia showed that treatment with transferrin injections markedly improved the
disturbances  in  iron  and  red  cell  turnover  characteristic  for  thalassemia  (Li et  al 2010,
Gelderman et al 2015).  Transferrin injections normalized labile plasma iron concentrations,
increased hepcidin expression, normalized red blood cell survival, increased hemoglobin
production, and concomitantly reduced reticulocytosis, erythropoietin level and
splenomegaly. These results suggested that transferrin is a limiting factor contributing to
anemia in thalassemic mice and suggested that transferrin therapy might be beneficial in
human beta-thalassemia. Considering the beneficial effects of transferrin injections on
inefficient erythropoiesis, transferrin could have therapeutic value in other diseases
associated with inefficient erythropoiesis.
Another potentially useful action of transferrin would be the binding of iron to inhibit the
growth of microbes dependent on iron supply.  The binding of free iron by intravenous
apotransferrin injections was shown to restore the growth inhibition of coagulase negative
staphylococci in the sera of stem cell transplantation patients, suggesting that apotransferrin
might protect patients against infections by opportunistic pathogens (von Bonsdorff  et  al
2003, von Bonsdorff  et al 2004).
In addition to the clinical use of transferrin in the native form it has been employed as a
targeting molecule. Transferrin has the potential to deliver guest molecules to cells
expressing transferrin receptors. Cancer and tumor cells with a high expression level of
transferrin receptors have been the target in most of these applications (Sato et  al 2000,
Iinuma et al 2002,  Suzuki et al 2008, Kim et al 2010).
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5. AIMS OF THE STUDY
The aims of this study were to prospectively investigate the appearance and detailed timing of
NTBI in patients undergoing hematopoietic stem cell transplantation and to study the effects
of administered exogenous apotransferrin on NTBI in patients undergoing allogeneic HSCT.
We also wanted to study in vitro the effect of NTBI on hematopoietic progenitor colony
formation, and the possibility to counteract this with apotransferrin. The specific study goals
were:
1. To determine the extent of the decline of serum transferrin and the liberation of iron, and
the appearance and exact timing of the presence of NTBI during allogeneic and autologous
HSCT.  For comparison, a group of patients treated with intensive chemotherapy only was
also studied.
2. To examine the kinetics and safety of a single i.v. dose of apotransferrin in allogeneic
HSCT patients.
3. To examine the kinetics, safety and tolerability of repeated i.v. doses of apotransferrin in
patients undergoing allogeneic HSCT.
4. To examine the effects of exogenous apotransferrin on the levels of serum total iron,
NTBI, transferrin saturation, and on the different iron saturation forms of transferrin.
5. To study the effect of NTBI (in the form of FeNTA, ferric nitrilotriacetic acid) on erythroid
and granulocyte macrophage colony formation in in vitro cultures, and the effect of
preincubation of FeNTA with apotransferrin on the colony growth.
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6. PATIENTS, MATERIALS AND METHODS
6.1. Patients
All patients were adults, over 18 years of age, and they were treated at the Division of
Hematology, Department of Medicine of the Helsinki University Central Hospital for
hematological malignancies between November 1996 and May 2000. For each study the
patients were enrolled consecutively during the time of the respective study.
6.1.1. Patients treated with allogeneic HSCT (I)
Ten consecutive patients undergoing allogeneic stem cell transplantation were enrolled in this
prospective  study.   There  were  equal  numbers  of  men  and  women.  All  received
myeloablative conditioning with cyclophosphamide (Cy) and total body irradiation (TBI).
Two patients had acute myeloid leukemia (AML) and three acute lymphoblastic leukemia
(ALL) in first remission; three had myelodysplastic syndrome (MDS), and two chronic
myeloid leukemia (CML). Nine patients received a bone marrow graft, seven from a sibling,
and  two  from  a  matched  unrelated  donor.  One  patient  was  transplanted  with  a  PBSC  graft
from a sibling.
6.1.2. Patients treated with autologous HSCT (II)
Sixteen consecutive patients who were admitted for intensive therapy with autologous stem
cell transplantation (aHSCT) were enrolled. Eleven had multiple myeloma (MM) (male n= 5,
female n= 6), four non-Hodgkin lymphoma (male n= 2, female n= 2), and one female patient
was treated for Hodgkin’s disease.  The conditioning for myeloma consisted of melphalan
and  TBI  (n=  7)  or  melphalan  monotherapy  (n= 4).  All the lymphoma patients were
conditioned with BEAC.
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6.1.3. Patients treated with cytotoxic chemotherapy (II)
Eight consecutive patients treated for acute leukemia were enrolled. All patients were male.
Four had AML, three ALL, and one had biphenotype acute leukemia.  Two patients received
cytotoxic chemotherapy as an induction and six as a consolidation treatment.
6.1.4. Patients given a single apotransferrin dose (III)
Seven consecutive patients undergoing conditioning with Cy/TBI for allogeneic HSCT and
meeting the inclusion and exclusion criteria were enrolled.  The inclusion criteria were serum
transferrin < 2 g/l and transferrin saturation > 80% on day -3 before the transplantation. The
exclusion criteria were clinically significant pulmonary or cardiovascular disease, or renal
insufficiency (serum creatinine > 115 μmol/l). Four of the patients were female, three male.
One female patient was excluded immediately prior to giving the study drug because of a
then emerging exclusion criterion. One patient had ALL and one AML.  Two of the patients
had CML in first chronic phase.  Of the two MDS patients, one had refractory anemia (RA)
and  the  other  refractory  anemia  with  excess  blasts  in  transformation  (RAEBt)  in  first
complete  remission.  One  patient  received  a  PBSC  graft  from  a  sibling;  all  others  were
transplanted with a bone marrow graft, two from a matched unrelated donor.
6.1.5. Patients given repeated doses of apotransferrin in a dose-finding study (IV)
Thirteen consecutive patients admitted for allogeneic HSCT with Cy/TBI and eligible for the
study were enrolled.  An inclusion criterion, in addition to age 18-65 years and Cy/TBI
conditioning, was weight ? 40 kg. The exclusion criteria were clinically significant
cardiovascular or pulmonary disease, renal insufficiency (serum creatinine > 115 μmol/l),
proteinuria,  complete  IgA deficiency,  or  participation  in  another  clinical  trial.    There  were
eight male and five female patients included in the study.  One male patient was excluded
after enrollment because the conditioning therapy and SCT were postponed for medical
reasons.   Five  patients  had  MM,  three  CML  in  chronic  phase,  two  had  MDS  (RAEB  and
RAEBt), one AML, and one patient had mantle cell lymphoma. Eleven of the patients
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received bone marrow, and only one a PBSC graft. Nine had a sibling and three an unrelated
donor.
6.1.6. Patients given repeated doses of apotransferrin in a high-dose setting (IV)
Eight consecutive patients, who met the same inclusion criteria as in the preceding study,
were  enrolled  in  this  high-dose  study  arm.   In  addition  to  those   of  the  previous  study,  the
exclusion criteria also included serum alanine aminotransferase ? 100 U/l (men), ? 70 U/l
(women),  serum  alkaline  phosphatase  >  275  U/l,  serum  bilirubin  >  20  μmol/l,  and  plasma
thromboplastin time ? 70%. Six of the patients were male and two female. Five patients
received a PBSC, and three a bone marrow graft.
6.2. Bone marrow samples for cell cultures (V)
The bone marrow samples used in the in vitro cell culture study were from healthy bone
marrow transplant donors.
6.3. Transplantation procedures
All patients who underwent allogeneic transplantation were conditioned with intravenous
cyclophosphamide 60 mg/kg body weight on two consecutive days (day -6 and day -5 in
relation to the transplantation on day 0) and TBI 12 Gy, fractionated in six doses from day -4
to day 0.  The immunosuppressive therapy consisted of  i.v. cyclosporine 3 mg/kg/day  as a
continuous infusion  starting on day -1, a short course of methotrexate (15 mg/m2 on day +1,
followed by  10mg/m2  on day +3 and  day +6), and oral methylprednisolone starting on day
+8. The initial methylprednisolone dose was 0.5 mg/kg for 7 days, then escalating to the
maximum of 1 mg/kg for 14 days. After that the dosage was reduced  to 0.5 mg/kg for 14
days, and thereafter the dose was slowly tapered and discontinued on day 112 (Ruutu et al
2000).
48
The conditioning treatment for autologous transplantation in myeloma patients was either
melphalan monotherapy (i.v. melphalan 100 mg/m2 on two consecutive days), or i.v.
melphalan 140 mg/m2 + fractionated TBI 12 Gy.  The preparative treatment for lymphoma
was BEAC: carmustine 300 mg/m2 on day 1, followed by  etoposide 100 mg/m2 x 2/day,
cytarabine  100 mg/m2 x 2/day, and cyclophosphamide 1500 mg/m2 x1 /day,  each for four
days (from day 2 to day 5).
6.4. Treatment for acute leukemia
The  treatment  was  based  on  the  underlying  disease  and  phase  of  therapy  and  followed  the
protocols in use at that time (Study II, Table 1).
6.5. Serum samples
The study samples, each a 10 ml vial, were mainly collected coinciding with routine
sampling. The timing schedules were somewhat different and are described in detail in each
study.  Extra sampling was done only in Study III to measure the study parameters after the
administration of the single dose of the study drug.
6.6. Laboratory methods
Serum total iron was measured by a colorimetric ferene-S method (reference range 8-30
μmol/l for women and 10-31 μmol/l for men). Serum transferrin was determined by an
immunoturbidimetric method (reference range 1.75-3.13 g/l).  Serum ferritin was measured
using the Ciba Corning ACS ferritin chemiluminometric immunoassay with a reference range
10-150 μg/l for women and 15-230 μg/l for men. Transferrin saturation was calculated using
the formula: serum iron (μmol/l)/serum transferrin (g/l) x 3.98  (Morgan 1992), without a
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cutoff at 100%.  The iron forms of transferrin were analyzed by urea polyacrylamide gel
electrophoresis  (6%  acrylamide  gel  with  6  mol/l  urea)  according  to  Williams  and  Moreton
(1980). Serum ferritin was measured using the Ciba Corning ACS Ferritin
chemiluminometric immunoassay.
6.7. NTBI
NTBI in serum was determined  using the bleomycin detectable iron (BDI) assay described
by Evans and Halliwell (Evans and Halliwell 1994).  In our studies it was performed
according to a modification for small serum volumes modified by our group. In this
modification all reactions were carried out in one-half the volumes using a
spectrophotometric microplate reader (von Bonsdorff et al 2002).  A detection limit of 0.1
μmol/l for NTBI was established based on the exclusion of interference of nonvisible
hemolysis and on accuracy studies. In the validation study BDI was found only when
transferrin saturation exceeded 80% (von Bonsdorff et al 2002).
6.8. Apotransferrin
The human  plasma-derived apotransferrin product was developed in the Finnish Red Cross
Blood Transfusion Service by means of purifying the Cohn fraction IV of human plasma by
two ion exchange chromatography steps and ultrafiltration in conformance with  good
manufacturing practice (GMP) requirements for an investigational new product (von
Bonsdorff et  al 2001). The process comprises solvent detergent treatment as the main virus
inactivation step and 15 nm virus filtration and polyethylene glycol precipitation as removal
steps for physico-chemically resistant infectious agents. Product characterization by
electrospray and MALDI-TOF mass spectrometry indicated no other chemical modifications
than N-linked glycan chains and disulphide bonds, except minor oxidation. The purity of the
product was more than 98%, main impurities being immunoglobulin (Ig)G, IgA and
hemopexin. The product had intact iron binding capacity and native conformation. The
apotransferrin solution was sterile, non-pyrogenic and suitable for i.v. use (von Bonsdorff et
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al 2001). A liquid formulation with 50 mg/ml apotransferrin stored at cold room temperature
was used throughout the clinical study.
6.8.1. Dosage of apotransferrin
6.8.1.1. Single dose (III)
During the myeloablative conditioning the  transferrin levels are usually decreased,  on
average 1.4-1.5 g/l on day +3 (Sahlstedt, unpublished data).  It was reasoned that a possible
clinical benefit could be achieved with a serum transferrin elevation by 2 g/l to reach the
upper  reference  limit  of  transferrin.  As  the  plasma volume of  an  adult  is  approximately  45
ml/kg, the goal would be reached with a dose of 100 mg/kg (0.1 g/kg divided by 0.045 l/kg).
The actual doses were rounded up to the nearest whole gram, and were given on day +3.
6.8.1.2. Repeated doses (IV)
In the dose-finding part, the higher apotransferrin dose, later in this review referred to as
medium-dose, was planned to increase the serum transferrin level and maintain it at 5-6 g/l.
That was estimated to be high enough to prevent the appearance of free iron in most patients.
The lower dose was planned to maintain the serum transferrin level at 2-3 g/l, which
approximately corresponds to the reference range in healthy humans.
The doses were calculated based on the results of Study III.  The loading doses of 100 mg/kg
we rounded up to the nearest whole gram. According to weight steps of 5 kg, starting from 40
kg up to > 104 kg, the actual loading dose varied between 91-111 mg/kg. The maintenance
dose was 1 g for patients ? 50 kg, 1.5 g for patients weighing between 50-59 kg, 2 g for
patients 60-99 kg, and 3 g for patients ? 100 kg. The average maintenance dose was 26
mg/kg (20-33 mg/kg).
The medium-dose arm received 4 loading doses from day -6 to day -3, and 8 maintenance
doses every other day from day -1 to day +13. The lower-dose arm received one loading dose
on day -6, and 9 maintenance doses every other day from day -4 to day +12.
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In this high-dose part, the dosage regimen was based on the results of the preceding dose-
finding part of the study, and the transferrin level was planned to reach 5-8 g/l on day -2.
With the five maintenance doses the basal transferrin level was anticipated to vary between 3-
6 g/l. Peak levels after apotransferrin infusions were estimated to be on the average 2.6 g/l
higher.
The average apotransferrin dose of 115 mg/kg was given to patients as a loading dose on four
consecutive days from day -6 to day -3, and as a maintenance dose every other day between
day -1 and day +7. The dose was rounded up to fit the package sizes of the study drug in the
different weight ranges: for patients weighing 40-54 kg the apotransferrin dose was 5.0 g, for
patients 55-74 kg 7.5 mg, and for patients ? 75 kg 10.0 g. Thus the actual dose varied
between 93 and 136 mg/kg.
6.9. Assessment of adverse effects of the study drug
The immediate tolerance was monitored before and during the two hours following the
injection by observing the blood pressure, pulse, temperature and respiratory rate. All other
adverse events were recorded at the same time points, and then 1, 2 and 3 days after the study
drug administration. The study drug safety was analyzed by monitoring blood counts, liver
and renal function and electrolyte balance in routine samples until day +10.
In patients receiving the low and medium dose of study drug, blood pressure and heart rate
were recorded just before, 15 minutes after the beginning of the loading infusion,
immediately after,  and 1 hour after the loading infusion. Body temperature was recorded
before and 1 hour after the loading infusion.
In patients receiving the high dose of the study drug, blood pressure and heart rate were
recorded at the first four infusions before, 15 minutes after the beginning and immediately
after the completion of each infusion. Body temperature was recorded before and
immediately after the first four infusions.
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Blood counts, liver and renal function and electrolyte balance, plasma thromboplastin time
and serum lactate dehydrogenase  were monitored in the routine samples until day +17 after
the dose-finding study, and until day +14 after the high dose study.
All events that impaired the well-being of the patient during the study period were recorded.
The causality in relation to the study drug was evaluated by the clinical researcher, and
graded to be non-related, improbable or possible. The maximum intensity of the adverse
effects was recorded as mild, moderate or severe.
According to the study protocol, in the high dose study-arm some symptoms or changes in
laboratory results, known to occur very frequently in HSCT patients, were not recorded as
adverse events. The symptoms and laboratory parameters not recorded as adverse events
were: fatigue, dry skin, mucositis, irritation of the insertion site of the central venous catheter,
or temperature increase up to 37.5 ? C, all changes in the blood counts, and serum levels of
bilirubin ? 30 μmol/l, alanine aminotransferase ? 150 U/l, alkaline phosphatase ? 600 U/l,
LD ? 700 U/l, and CRP ? 30 mg/l, as well as thromboplastin time ? 50%.
6.10. Ferric nitrilotriacetic acid (FeNTA)
Ferric nitrilotriacetic acid (FeNTA) was prepared from an iron atomic absorption standard
solution and 5mM nitrilotriacetic acid (NTA) dissolved in 0.1 M Tris buffer, pH 8.0.  The
final solution contained 3 mM Fe3+ pH 7.4.  The final concentration of free iron in the culture
medium was confirmed by the BDI-assay described above. The detected levels of free iron
were about 70% of the added concentration of FeNTA, but the results are given according to
the added FeNTA concentration.
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6.11. In vitro cultures of hematopoietic progenitors
Erythroid burst-forming units (BFU-E) and granulocyte-macrophage colony-forming units
(CFU-GM) of healthy bone marrow transplant donors were cultured in a methyl cellulose
assay according to Juvonen et al (1993).  Three to five ml of bone marrow was aspirated and
diluted to Iscove’s Modified Dulbecco’s Medium (IMDM) containing heparin (Iscove et al
1974). Mononuclear cells (MNC) were isolated by gradient centrifugation, washed and
resuspended in IMDM. The culture medium consisted of 0.8% methyl cellulose, 20%  fetal
calf serum,1% delipidated and deionized bovine serum albumin, 10-4 M mercaptoethanol, 310
μg/ml fully iron saturated  transferrin (Sigma-Aldrich), 20% human leukocyte conditioned
medium prepared in IMDM, and IMDM. The growth of erythroid progenitors was stimulated
with recombinant human erythropoietin 2 U/ml (EPO, Cilag AG). The growth of CFU-GM
was stimulated with bladder cancer cell line 5637-conditioned medium described by
Coutinho et al (1990). Plates were incubated at 37 ? C in a fully humidified atmosphere with
5% CO2.  Both  BFU-E  and  CFU-GM  were  scored  on  the  14th day  of  culture.    The  final
concentration of free iron in the culture medium was confirmed by the BDI-assay (von
Bonsdorff  et al 2002). For cultures with apotransferrin FeNTA was preincubated for 60 min
in 37?C with 4 mg/ml of apotransferrin.
6.12. Statistical analyses
In study II the differences of the transferrin saturation levels and the proportion of the NTBI-
positive samples between the different study groups were analyzed by using the Kruskal-
Wallis  test.  In  Study  IV  the  statistical  differences  were  determined  by  two-way  Anova  for
repeated measurements to test null hypothesis regarding the effects of between-subject factor
(dose group), the within-group factor (day), and the interaction between them. Post hoc tests
were used to evaluate differences between the dose groups.  The influence of apotransferrin
infusion  on  serum  iron  levels  were  tested  by  paired t-test. The Wilcoxon signed ranks test
was used in the cell culture study (Study V) to determine the significant level of the
nitrilotriacetic  acid  (FeNTA) concentration  which  has  an  effect  on  the  number  of  erythroid
burst-forming unit (BFU-E) colonies.
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6.13. Approvals
The studies were approved by the Ethics Committee of the Helsinki University Central
Hospital. The apotransferrin studies were also approved by the National Agency for
Medicines.   All  patients  were  enrolled  after  giving  their  informed  consent.  The  use  of  the
donated cells also in scientific studies was approved by the bone marrow donors.
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7. RESULTS
7.1. NTBI during allogeneic HSCT (I)
The baseline samples were collected on day -10 to -6, and the daily samples from the day
after the start of conditioning, i.e. from day -5 on, until day +14 in relation to the
transplantation (day 0).
During the first two days after starting the conditioning the mean total iron concentration
doubled from the initial level to a peak on day -4 before transplantation. The transferrin levels
decreased continuously and fully saturated transferrin was observed with the occurrence of
NTBI by day -4. The mean transferrin saturation remained above 80% thereafter. NTBI was
detectable in the majority of patients until day +11, remaining present in half of the patients
through the study period until day +14. NTBI was detectable on average for 14.2 days (6-18
days),  representing  77%  (30-100%)  of  the  samples.  In  the  three  patients  who  were  NTBI-
positive already at baseline, the transferrin saturation was already then above 80%.
NTBI was detected in 88% of the samples with transferrin saturation above 80% and only in
8% of the samples with transferrin saturation below 80%. Thus we found the transferrin
saturation of  80% to be a significant threshold for the appearance of NTBI.
7.2. NTBI during autologous HSCT (II)
The serum samples referred to as baseline were collected 0-3 days before the start of the
preparative regimen. Further samples were collected daily with routine sampling during the
first  20  days  after  the  onset  of  each  regimen;  the  mean number  of  samples  per  patient  was
18.5 (range 16-21).
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The mean transferrin levels were within the normal range at baseline, started to descend from
the beginning of chemotherapy, and decreased through the study period in all the different
aHSCT-groups.
The mean transferrin saturation levels were also within the normal range at baseline. After a
steep rise within the first days after the initiation of conditioning, the maximum levels were
reached approximately at day 4-6 in all groups.  The levels started to descend approximately
one week after the beginning of each regimen. The transferrin saturation level of the
melphalan-group was significantly lower than in the BEAC-group (p= 0.0002).
None of the patients were NTBI-positive at baseline, and three of them (1 melphalan
monotherapy, 2 melphalan/TBI) remained NTBI-negative through the whole study period. In
all  the  other  patients  NTBI  was  detected  variably,  the  mean  time  from  the  first  to  the  last
NTBI-positive  sample  in  the  aHSCT-group  as  a  whole  being  6.1  days.  Overall,  NTBI  was
detected  in  22%  of  the  samples.   The  disappearance  or  marked  reduction  of  the  NTBI-
positive samples coincided with the recovery of the bone marrow function demonstrated by
the rise in the leukocyte counts.
7.3. NTBI during chemotherapy (II)
The baseline samples were collected 0-3 days before initiating the treatment and the samples
were taken thereafter daily with routine sampling for 20 days.  The mean number of samples
per patient was 15.5 (7-21).   The mean transferrin and transferrin saturation were below the
reference range at baseline, and the transferrin level remained subnormal thereafter. The
mean  transferrin  saturation  showed  a  steep  rise  above  90%  by  day  3  from  the  start  of
chemotherapy, and remained above 80% through the study period.
NTBI was detected already at baseline in nearly 40% of the samples. The proportion of the
NTBI-positive samples remained high during the whole study period, with an overall
proportion of 59%.  The average duration of NTBI-positivity was 15.6 days.  No leukocyte
recovery was seen during the study period.
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7.4. Effects of a single intravenous dose of apotransferrin (III)
A single dose of 100 mg/kg of human apotransferrin was given as a slow (30 min) injection
in a deep vein catheter on day +3 post-HSCT. Serum transferrin, total iron, NTBI, transferrin
saturation  and transferrin iron forms were determined from blood samples drawn
immediately prior to the study drug administration, and at 15 min, 2 h and 12 h after the
study drug injection. Thereafter the samples were drawn daily in the morning for the first 6
days and then on day +8, +10 and day +12 after the study drug administration.
7.4.1. Transferrin
The serum transferrin level before the apotransferrin injection was below the lower reference
limit in all patients, the mean being 1.51 g/l (1.07-1.74 g/l). After the apotransferrin
administration, the serum concentration increased by an average of 1.95 g/l (1.48-2.42 g/l).
The mean serum transferrin at the 15 min sample was 3.46 g/l (3.06-4.04 g/l), with a rapid
decline during the first day and slower decline thereafter. The calculated provisional
elimination-phase half-life between days 1 and 5 after the administration was 4.8 days.
7.4.2. Iron
The mean serum iron level rose from an initial 35 μmol/l (24-38 μmol/l) to a peak value of 53
μmol/l (26-66 μmol/l) at 24 hours after the injection.
7.4.3. Transferrin saturation
The transferrin saturation decreased from the mean of 91% (87-94%) to 42% (30-49%) 15
min after the apotransferrin injection. After 2 hours the transferrin saturation started to
increase in all patients, but in an individually variable course. The saturation exceeded 80%
in three patients 12-24 hours after the injection, in one patient 2 days, and in another patient 6
days after the apotransferrin dose. In one patient the transferrin saturation remained below
80% during the whole 12 day follow-up period.
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7.4.4. NTBI
Before the apotransferrin injection all samples were positive for NTBI. Immediately after the
apotransferrin dose, serum NTBI became undetectable in all patients. One patient remained
NTBI negative through the 12-day follow-up period. NTBI reappeared 12-24 hours after the
apotransferrin injection in 4 patients and after 6 days in one.  In these five patients NTBI
reappeared showing a close association with the transferrin saturation increase above 80%.
NTBI remained undetectable in the one patient whose transferrin saturation levels did not
exceed 80%.
7.4.5. (Apo)transferrin conversion
The conversion of the given apotransferrin into monoferric and diferric transferrin forms was
monitored by urea gel electrophoresis in sequential serum samples after the injection. At 15
min iron-free and monoferric forms appear in the sera of all patients.  The amount of the
diferric transferrin remained relatively unchanged in five patients, but was reduced in one.
Later the iron-free form disappeared first, the monoferric form remained detectable longer,
while the amount of the diferric form increased, indicating apotransferrin conversion first to
monoferric and further to diferric form. The conversion coincided with the increase in the
transferrin saturation.
The amount of iron bound by the administered apotransferrin during the first 15 minutes was,
on average, 16 μmol/l (11-22 μmol/l), as calculated from the amount of formed monoferric
transferrin.
7.4.6. Ferritin
Four of the six patients had their serum ferritin levels above the reference range before the
beginning of the myeloablative regimen. Three of them had serum ferritin level ? 1000 μg/l.
A correlation was found between the baseline serum ferritin and the occurrence of NTBI after
the apotransferrin dose. The patients with ferritin > 1000 μg/l had NTBI in 72% of serum
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samples, whereas only 19% of the samples were NTBI-positive when baseline ferritin was
<1000 μg/l (p ? 0.0001).
7.5. Effects of repeated apotransferrin administrations (IV)
Twenty patients received repeated doses of apotransferrin.  The ten patients in our first study
(Study I) who underwent HSCT but were not given apotransferrin were used as controls.
7.5.1. Low and medium dose of apotransferrin
In the first part of the study, twelve patients were randomized to receive the study drug at two
dose levels. The low-dose group (n= 6) received a total dose of 340 mg/kg, given as a single
loading dose of 100 mg/kg on day -6, followed by nine maintenance doses of  26 mg/kg
(mean) every other day, until day +12. The medium-dose group (n= 6) received a total dose
of 610 mg/kg, given as four loading doses of 100 mg/kg on four consecutive days starting on
day -6, followed by eight maintenance doses of 26 mg/kg (mean) every other day until day
+13.
7.5.2. High dose of apotransferrin
In the second part of the study, eight patients received a total dose of 1040 mg/kg, given as
four daily doses of mean 115 mg/kg from day -6 until day -3, continuing every second day
until day +7 after HSCT.
7.5.3. Transferrin
As a result of the apotransferrin administration, the transferrin levels during the
administration period were significantly higher in the high-dose group than in the groups
given lower doses or in the controls, whereas there were no significant differences between
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the low and medium-dose groups and the controls. In the high-dose group, the initial average
level of transferrin was 2.2 g/l, after the first two to three apotransferrin doses it increased to
? 4.0 g/l and remained between 3-6 g/l during the 10-day period when infusions were given
every other day. This maintenance level of transferrin was in average 3.0 g/l (95% confidence
interval (CI) 2.2-2.8 g/l) higher than in the control group during the dosing period until day
+7 after transplantation.
7.5.4. Iron
In the high-dose group the mean serum iron level increased from the mean pretreatment level
of 11 μmol/l to 32 μmol/l after the first infusion and to 80 μmol/l after the second infusion.
Thereafter there was individual variation, the levels reaching ?100 μmol/l in five patients,
and remaining constant or decreasing in the other three patients. The iron concentrations were
at their peak on the second day after the start of conditioning, with the mean increase in
serum iron being 48 μmol/l/d.
The serum iron levels rose significantly higher in the high-dose group than in the low-dose
group (p??0.05)  and  controls  (p??0.01).  Although there was a dose-dependent trend in the
mean iron levels in the low- and medium-dose groups, the groups did not differ significantly
from each other or from the controls.
After the initial rise, the serum iron levels remained on a highly elevated level for 10 days
(from day -4 to day +5), mainly returning into the reference range by day +14. This coincided
with the appearance of reticulocytes in the peripheral blood, which took place between days
+6 and + 14 in most patients.
7.5.5. Transferrin saturation
In the high-dose group the transferrin saturation was significantly lower than in the controls.
The mean transferrin saturation was 70% during the period when the serum iron was highly
elevated  (from  day  -4  to  day  +5).  During  this  period  the  average  difference  to  the  control
group was 22.6% (95% CI 3.7- 41.4%). The average increase in transferrin saturation in the
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high-dose group was 49% during the 4 days after the initiation of the conditioning.
Calculating from the increment of iron saturation and the amount of endogenous and
administered apotransferrin, an average 180 μmol of iron per day was bound to transferrin
during the first 4 days after the start of conditioning regimen.
7.5.6. NTBI
In the control group the patients were NTBI-positive for most of the study period, the mean
proportion of NTBI positive days being 75% (95% CI 60-92%).
In the high-dose group five of the eight patients had transferrin saturation ? 80% and were
NTBI negative through the study period.  The average proportion of NTBI-positive days was
20% (95% CI 0-43%), which was significantly lower than in the control group (p= 0.001).
7.6. Tolerability and adverse effects of apotransferrin administration (III, IV)
7.6.1. Single dose
No serious adverse effects during the 12-day follow-up period were noted. There were no
clinically significant changes in the vital signs in association with the injection, and the
immediate general tolerability was good.  One improbable association with the study drug in
the form of a mild, spontaneously subsided chilly feeling in one patient was discovered.
7.6.2. Repeated doses
No serious adverse events were encountered. In the high-dose group 228 non-serious adverse
effects were recorded during the 21-day follow-up period. The maximum intensity was
graded severe in six events and moderate or mild in all the other. The causal relationship with
the study drug was assessed as not related in 223 events, improbable in four and possible in
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one  (serum  alanine  aminotransferase  elevation).  In  none  of  the  events  was  the  causality
assessed as probable.
7.7. Effect of NTBI on erythroid and granulocyte-macrophage colony formation;
counteraction with apotransferrin (V)
Erythroid colonies of 17 and granulocyte-macrophage colonies of nine healthy bone marrow
transplant  donors  were  cultured  from  bone  marrow  samples  without  or  with  varying
concentrations of free iron (FeNTA).  In the cultures without FeNTA the median number of
BFU-E colonies was 138 (range 60-251) and that of CFU-GM colonies 293 (range 163-514)
per 1 x 105 cells.
7.7.1. Effect of FeNTA
The addition of FeNTA to the cultures suppressed both BFU-E and CFU-GM colony
formation in a dose dependent manner. Besides colony numbers, also the size of the erythroid
colonies decreased in the presence of free iron.  Most colonies seen in the cultures with
FeNTA concentrations ?30 μmol/l were very small, though bright red indicating
hemoglobinization. Free iron also reduced the number and size of granulocyte-macrophage
colonies in a dose-dependent manner.
7.7.2. Effect of apotransferrin
The possible protective effect of transferrin was studied in seven BFU-E and five CFU-GM
cultures with different iron concentrations, with or without the preincubation of FeNTA with
apotransferrin. The binding of free iron to transferrin reduced statistically significantly the
inhibition of colony formation in erythroid and granulocyte-macrophage cultures; the colony
numbers and the size of the colonies normalized.
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8. DISCUSSION
In the present series of studies we evaluated prospectively the appearance of non-transferrin-
bound iron and its timing during the peritransplantation period in HSCT. For comparison, we
also investigated the occurrence of NTBI after conventional combination chemotherapy. To
measure NTBI, the bleomycin-detectable iron method was used. We studied whether it is
possible to eliminate or reduce the appearance of NTBI with apotransferrin administration,
what the kinetics of apotransferrin in this context is, and whether this novel approach is safe.
The effect of NTBI on hematopoietic progenitors in in vitro cultures was also studied.
We found NTBI in all patients shortly after the start of conditioning for allogeneic stem cell
transplantation and the appearance of NTBI to coincide with completely saturated serum
transferrin.  In  our  study  we  could  demonstrate,  for  the  first  time,  the  exact  timing  and
duration of the changes in transferrin saturation and the appearance and the length of the
presence of NTBI in the peritransplatation period.  We could also show and confirm the 80%
saturation of transferrin to be a reliable threshold for NTBI.
We used the BDI assay for NTBI measurement,  because it  has a high specificity for NTBI,
does not measure ferritin-bound iron, and because it measures the biochemical reaction
between bleomycin and the redox-active iron. This method gives clearly lower NTBI levels
than  methods  based  on  the  mobilization  of  NTBI  with  a  chelator  and  determination  of  the
ultrafiltered iron-chelator complex. Therefore our results for NTBI concentrations were lower
than those shown in previous reports (Bradley et al 1997, Dürken et al 1997). In these reports
NTBI was measured using chelation with nitrilotriacetic acid,  a step that also can remove a
fraction of transferrin-bound iron, and therefore may show false positive results.
In our studies NTBI was also detectable in the majority of patients undergoing autologous
stem cell transplantation and the intensity of the conditioning also seemed to have an effect
on the appearance of NTBI. Patients conditioned with melphalan monotherapy had a lower
proportion of NTBI-positive samples than those given melphalan with TBI or BEAC.
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A clear finding was that the presence of NTBI coincided with bone marrow suppression, and
NTBI largely disappeared at the recovery of the bone marrow function and reutilization of
iron by the recovering marrow. Our observation of the normalization of the transferrin
saturation with the same timing, despite the continuous decrease in the transferrin
concentration, also supports this conclusion.
Patients who were treated with intensive cytotoxic chemotherapy, but did not receive stem
cell rescue, experienced the longest bone marrow suppression and the most prolonged
presence of NTBI, and showed complete saturation of transferrin. The coinciding presence of
NTBI and neutropenia has also been reported by Harrison et al (1994). The appearance of
NTBI after high-dose chemotherapy as a consequence of halted erythropoietic activity has
been originally suggested by Bradley et al (1997). Other possible causes for extracellular iron
accumulation after myeloablative conditioning include the destruction of malignant cells and
hepatocellular injury (Evens et al 2004).
The  cytotoxicity  of  NTBI,  which  has  been  suggested  to  play  a  role  in  the  pathogenesis  of
many injuries associated with intensive cytotoxic therapy, has been confirmed by several
lines of evidence (Anderson 1999, Smirnov et al 1999).  Ferric iron has been shown to cause
cytotoxicity after a few hours in liver cell cultures (Sakurai and Cederbaum 1998, Morel et al
1990). In our in vitro-study we found that NTBI caused a significant suppression of the
colony formation of normal hematopoietic progenitor cells.  Preincubation with
apotransferrin partly prevented the toxic effects of free iron on erythroid and granulocyte-
macrophage colony formation.
The effect of binding NTBI with apotransferrin and the possible influence on iron-induced
complications was the rationale behind our studies with exogenous apotransferrin given to
patients undergoing allogeneic stem cell transplantation. To our knowledge, this setting was
the first use of any iron-chelating agent in HSCT patients.
We  found  that  with  a  single  apotransferrin  dose  NTBI  disappeared  from  the  sera  of  all
patients,  indicating  that  it  was  effectively  bound.   The  effect  was  also  demonstrated  by  the
conversion of transferrin into monoferric and diferric forms in the sequential serum samples
after the apotransferrin injection.  The stable appearance of diferric transferrin suggested that
the iron bound by the given apotransferrin represented NTBI and was not shuttled from fully
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saturated endogenous transferrin.  NTBI remained undetectable for a variable time, ranging
from a few hours to several days. In most patients the reappearance of NTBI occurred 12-24
hours after the apotransferrin injection.
NTBI probably comprises heterogeneous iron complexes which may differ in their binding to
chelating agents and whose proportions may differ in different clinical conditions (Breuer et
al 2000a, Breuer et  al 2000b). The disappearance of bleomycin-detectable NTBI after the
apotransferrin injection indicated that the redox-active iron in the sera of the HSCT patients
was in a form that was effectively bound by transferrin.
The apotransferrin injection resulted in a temporary rise in the serum total iron concentration,
which continued at a variable rate and leveled off at 24 h in most patients. This may indicate
that  iron  was  not  only  released  from  the  catabolism  of  senescent  erythrocytes,  but  also
mobilized from insoluble complexes by the given apotransferrin.
With repeated doses of apotransferrin, the highest doses given prevented full transferrin
saturation in five of the eight patients studied.  Based on the increment of iron saturation and
the amount of endogenous and administered apotransferrin, it could be concluded that an
average of 180 μmol/d of iron was bound to transferrin during the first 4 days after the onset
of conditioning. Subsequently, the iron accumulation leveled off in most patients indicating
that a new equilibrium was reached.
Repeated apotransferrin doses were followed by a much steeper rise in serum iron than the
increment that occurred in the control patients. The increase in serum iron was in concert
with the amount of apotransferrin given, which may suggest that apotransferrin induced iron
release from tissues.  However, during the period of highly elevated serum iron,
apotransferrin doses were followed by a significant increase in serum iron only in patients
with fully saturated transferrin and NTBI in their serum, whereas no significant change in
serum iron took place in the patients with partially saturated transferrin.  This suggests that,
rather than inducing iron release from cells, apotransferrin may have rendered the poorly
soluble NTBI into a transferrin-bound, soluble form, thus causing the increase in measurable
iron.
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Supporting the conclusion that apotransferrin did not induce iron release from macrophages,
most (Esparza and Brock 1981, Brock et al 1984, Saito et  al 1986), but not all (Rama et  al
1988) in vitro studies with monocyte/macrophages have failed to show any effect of excess
apotransferrin or transferrin or transferrin saturation on iron release. Furthermore, giving
large amounts of apotransferrin to animals did not modify iron donation by tissue (Lipschitz
et al 1971, Finch et al 1982). In human studies no correlation between transferrin saturation
level and release of radioactive iron to plasma has been observed (Stefanelli et al 1984, Fillet
et al 1989).
The results of our studies underline the transient erythroid arrest as the main reason for iron
accumulation, as the majority of the patients studied were in complete remission and most
had no signs of liver injury. Furthermore, the rapid normalization of the highly elevated
serum  iron  levels  concomitantly  with  the  start  of  graft  erythropoiesis  supports  the  close
association between extracellular iron accumulation and erythropoietic activity.
It remains unknown whether maintenance of the released extracellular iron in transferrin-
bound form is less harmful than the accumulation of NTBI during the erythropoietic arrest
following myeloablation. The maintenance of iron in the transferrin-bound form should
prevent its rapid intake by the liver and other non-hematopoietic tissues and the consequent
iron-induced toxicity. Apotransferrin binds NTBI into a physiological form that can be
utilized by the recovering erythroid marrow. As the erythroid progenitors take up a lot of
transferrin-bound iron and, as we have shown, the HSCT patients have low endogenous
transferrin level, increase in the circulating transferrin pool might promote the recovery of the
graft. Also, in  murine in vivo-models pretreatment of mice with transferrin protected marrow
cells against gamma-irradiation-induced death (Lesnikov et al 2001) and prevented  Fas-
mediated hepatocyte death and liver failure (Lesnikov et al 2004). The cytoprotective effects
were also shown in our own in vitro hematopoietic colony formation studies with excess iron
without and with preincubation with apotransferrin.  Furthermore, transferrin withholds iron
from most opportunistic bacteria and fungi, thus protecting patients from infections (Harrison
et al 1994, Iglesias-Osma et  al 1995, Matinaho et  al 2001). We have also shown that
apotransferrin prevents the growth of Staphylococcus epidermidis in vitro by binding the
NTBI in the sera of HSCT patients (von Bonsdorff et al 2003, von Bonsdorff  et al 2004).
Therefore, there are several mechanisms by which the administration of apotransferrin might
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prove beneficial to patients treated with intensive cytotoxic treatment, including HSCT
patients.
The feasibility, efficacy to prevent complications, administration policy and dosing of
apotransferrin in the clinical setting remain to be evaluated. Our study with repeated
apotransferrin administrations showed that the highest dosage used was effective in binding
NTBI in most patients, and this administration policy might offer a baseline for such studies.
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9. SUMMARY
We showed that NTBI appears regularly during the peritransplant period in HSCT. This is
largely  due  to  reduced  utilization  of  iron  by  erythropoiesis  and  the  reduction  of  serum
transferrin levels caused by the transplantation process. As NTBI might contribute to the
complications of HSCT, we assessed the possibility to bind NTBI during the peritransplant
period with apotransferrin infusions. We showed that the appearance of NTBI could be
prevented or reduced by apotransferrin. Our in vitro study demonstrating the toxic effect of
NTBI on hematopoietic progenitors and the beneficial effect of binding NTBI with
apotransferrin on colony growth supports the possibility that binding of NTBI with
apotransferrin  infusions  may  turn  out  to  be  clinically  useful.  The  clinical  utility  of
apotransferrin administration and the effects on transplantation outcomes remain to be
investigated in further studies.
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